DETERMINATION OF CANCEROUS CONDITIONS BY MAGE GENE EXPRESSION

Abstract: A method for determining cancers is described. The method involves assaying for expression of a gene coding for at least one of MAGE tumor rejection antigen or its precursor expression product.

Description: DETERMINATION OF CANCEROUS CONDITIONS BY MAGE GENE EXPRESSION FIELD OF THE INVENTION This invention relates to general methods for diagnosing cancers via determining expression of at least one member of the MAGE family of tumor rejection antigen precursors. More particularly, cancers such as lung adenocarcinoma, neck, squamous cell, prostate, and bladder cancers can be diagnosed by determining expression of one or more members of this family of genes. Also a part of the invention are primers which can be used in these methods, such as amplification methods, of which the polymerase chain reaction ("PCR") is the most well known. BACKGROUND AND PRIOR ART The study of the recognition or lack of recognition of cancer cells by a host organism has proceeded in many different directions. Understanding of the field presumes some understanding of both basic immunology and oncology. Early research on mouse tumors revealed that these displayed molecules which led to rejection of tumor cells when transplanted into syngeneic animals. These molecules are "recognized" by T-cells in the recipient animal, and provoke a cytolytic T-cell response with lysis of the transplanted cells. This evidence was first obtained with tumors induced in vitro by chemical carcinogens, such as methylcholanthrene. The antigens expressed by the tumors and which elicited the T-cell response were found to be different for each tumor. See Prehn, et al., J. Natl. Cane. Inst. 18: 769-778 (1957); Klein et al. , Cancer Res. 20: 1561-1572 (1960); Gross, Cancer Res. 3: 326-333 (1943), Baso brio, Cancer Res. 30: 2458-2462 (1970) for general teachings on inducing tumors with chemical carcinogens and differences in cell surface antigens. This class of antigens has come to be known as "tumor specific transplantation antigens" or "TSTAs". Following the observation of the presentation of such antigens when induced by chemical carcinogens, similar results were obtained when tumors were induced in vitro via ultraviolet radiation. See Kripke, J. Natl. Cane. Inst. 53: 333-1336 (1974). While T-cell mediated immune responses were observed for the types of tumor described supra. spontaneous tumors were thought to be generally non-immunogenic. These were therefore believed not to present antigens which provoked a response to the tumor in the tumor carrying subject. See Hewitt, et al., Brit. J. Cancer 33: 241-259 (1976). The family of turn " antigen presenting cell lines are im unogenic variants obtained by mutagenesis of mouse tumor cells or cell lines, as described by Boon et al., J. Exp. Med. 152: 1184-1193 (1980), the disclosure of which is incorporated by reference. To elaborate, turn" antigens are obtained by mutating tumor cells which do not generate an immune response in syngeneic mice and will form tumors (i.e., , "turn "1" " cells). When these tum + cells are mutagenized, they are rejected by syngeneic mice, and fail to form tumors (thus "turn""). See Boon et al., Proc. Natl. Acad. Sci. USA 74: 272 (1977), the disclosure of which is incorporated by reference. Many tumor types have been shown to exhibit this phenomenon. See, e.g., Frost et al., Cancer Res. 43: 125 (1983). It appears that turn " variants fail to form progressive tumors because they initiate an immune rejection process. The evidence in favor of this hypothesis includes the ability of "turn " " variants of tumors, i.e., those which do not normally form tumors, to do so in mice with immune systems suppressed by sublethal irradiation, Van Pel et al., Proc. Natl. Acad. Sci. USA 76: 5282-5285 (1979); and the observation that intraperitoneally injected turn" cells of mastocytoma P815 multiply exponentially for 12-15 days, and then are eliminated in only a few days in the midst of an influx of lymphocytes and macrophages (Uyttenhove et al., J. Exp. Med. 152: 1175-1183 (1980)). Further evidence includes the observation that mice acquire an immune memory which permits them to resist subsequent challenge to the same turn" variant, even when immunosuppressive amounts of radiation are administered with the following challenge of cells (Boon et al., Proc. Natl, Acad. Sci. USA 74: 272-275 (1977); Van Pel et al., supra; Uyttenhove et al., supra) . Later research found that when spontaneous tumors were subjected to mutagenesis, immunogenic variants were produced which did generate a response. Indeed, these variants were able to elicit an immune protective response against the original tumor. See Van Pel et al., J. Exp. Med. 157: 1992-2001 (1983). Thus, it has been shown that it is possible to elicit presentation of a so-called "tumor rejection antigen" in a tumor which is a target for a syngeneic rejection response. Similar results have been obtained when foreign genes have been transfected into spontaneous tumors. See Fearon et al., Cancer Res. 48: 2975-1980 (1988) in this regard. A class of antigens has been recognized which are presented on the surface of tumor cells and are recognized by cytolytic T cells, leading to lysis. This class of antigens will be referred to as "tumor rejection antigens" or "TRAs" hereafter. TRAs may or may not elicit antibody responses. The extent to which these antigens have been studied, has been via cytolytic T cell characterization studies, in vitro i.e., the study of the identification of the antigen by a particular cytolytic T cell ("CTL" hereafter) subset. The subset proliferates upon recognition of the presented tumor rejection antigen, and the cells presenting the antigen are lysed. Characterization studies have identified CTL clones which specifically lyse cells expressing the antigens. Examples of this work may be found in Levy et al., Adv. Cancer Res. 24: 1-59 (1977); Boon et al., J. Exp. Med. 152: 1184-1193 (1980); Brunner et al., J. Immunol. 124: 1627-1634 (1980); Maryanski et al., Eur. J. Immunol. 124: 1627-1634 (1980); Maryanski et al., Eur. J. Immunol. 12: 406-412 (1982); Palladino et al., Cane. Res. 47: 5074-5079 (1987). This type of analysis is required for other types of antigens recognized by CTLs, including minor histocompatibility antigens, the male specific H-Y antigens, and the class of antigens referred to as "turn-" antigens, and discussed herein. A tumor exemplary of the subject matter described supra is known as P815. See DePlaen et al., Proc. Natl. Acad. Sci. USA 85: 2274-2278 (1988); Szikora et al. , EMBO J 9: 1041-1050 (1990), and Sibille et al. , J. Exp. Med. 172: 35-45 (1990), the disclosures of which are incorporated by reference. The P815 tumor is a mastocytoma, induced in a DBA/2 mouse with methylcholanthrene and cultured as both an in vitro tumor and a cell line. The P815 line has generated many turn " variants following mutagenesis, including variants referred to as P91A (DePlaen, supra) , 35B (Szikora, supra) , and P198 (Sibille, supra) . In contrast to tumor rejection antigens - and this is a key distinction - the turn" antigens are only present after the tumor cells are mutagenized. Tumor rejection antigens are present on cells of a given tumor without mutagenesis. Hence, with reference to the literature, a cell line can be tum + , such as the line referred to as "PI", and can be provoked to produce turn' variants. Since the turn" phenotype differs from that of the parent cell line, one expects a difference in the DNA of turn" cell lines as compared to their tum + parental lines, and this difference can be exploited to locate the gene of interest in turn' cells. As a result, it was found that genes of turn " variants such as P91A, 35B and P198 differ from their normal alleles by point mutations in the coding regions of the gene. See Szikora and Sibille, supra. and Lurquin et al., Cell 58: 293-303 (1989). This has proved not to be the case with the TRAs of this invention. These papers also demonstrated that peptides derived from the turn " antigen are presented by the L d molecule for recognition by CTLs. P91A is presented by L d , P35 by D d and P198 by K d . PCT application PCT/US92/04354, filed on May 22, 1992 assigned to the same assignee as the subject application, teaches a family of human tumor rejection antigen precursor coding genes, referred to as the MAGE family, and their expression in various tumor types. Lung adenocarcinoma is not among these. Several of these genes are also discussed in van der Bruggen et al., Science 254: 1643 (1991). It is now clear that the various genes of the MAGE family are expressed in tumor cells, and can serve as markers for the diagnosis of such tumors, as well as for other purposes discussed therein. See also Traversari et al., Immunogenetics 35: 145 (1992); van der Bruggen et al., Science 254: 1643 (1991) . The mechanism by which a protein is processed and presented on a cell surface has now been fairly well documented. A cursory review of the development of the field may be found in Barinaga, "Getting Some 'Backbone': How MHC Binds Peptides", Science 257: 880 (1992); also, see Fremont et al., Science 257: 919 (1992); Matsumura et al., Science 257: 927 (1992); Latron et al. , Science 257: 964 (1992). These papers generally point to a requirement that the peptide which binds to an MHC/HLA molecule be nine amino acids long (a "nonapeptide") , and to the importance of the first and ninth residues of the nonapeptide. Studies on the MAGE family of genes have now revealed that, in some cases a nonapeptide is presented on the surface of tumor cells, and that the presentation of the nonapeptide requires that the presenting molecule be HLA- Al. Complexes of the MAGE-1 tumor rejection antigen (the "TRA" or nonapeptide") leads to lysis of the cell presenting it by cytolytic T cells ("CTLs") . Additional research has correlated other nonapeptides derived from MAGE and genes to HLA-A1 and other MHC class I molecules. Research presented in, e.g., U.S. patent application Serial No. 07/938,334 filed August 31, 1992, showed that, when comparing homologous regions of various MAGE genes to the region of the MAGE-1 gene coding for the relevant nonapeptide, there is a great deal of homology. The nucleic acid sequences which code for the nonapeptides were also described therein. These nucleic acid molecules were described as also being useful as diagnostic probes for tumor presence. The application also showed how it had been found that a cellular model could be used, wherein a non-human cell can be transfected with a nucleic acid sequence coding for a human HLA molecule. The resulting transfectant could then be used to test for nonapeptide specificity of the particular HLA molecule, or as the object of a second transfection with a MAGE gene. The co-transfectant could be used to determine whether the particular MAGE based TRA is presented by the particular HLA molecule. Many of the references referred to supra present data on the. expression pattern of various MAGE genes in different types of cell lines and tumor tissues. What is evident from these data is that there is no "unifying principle" which allows one to predict which MAGE gene will be expressed by a particular tumor type. Thus, while on one level one can say that MAGE genes are "markers" for tumors, on the level of specific tumor types, the correlation of marker and tumor type is not predictable, and must be determined empirically. It has now been found that one can carry out cancer determination assays by assaying for expression of one or more members of the MAGE family of tumor rejection antigen precursors. How this is accomplished is shown in the examples which follow. BRIEF DESCRIPTION OF THE FIGURES Figures 1A and IB depict detection of transfectants expressing antigen P815A. Figure 2 shows the sensitivity of clones Pl.HTR, PO.HTR, genomic transfectant P1A.T2 and cosmid transfectant P1A.TC3.1 to lysis by various CTLs, as determined by chromium release assays. Figure 3 is a restriction map of cosmid CIA.3.1. Figure 4 shows Northern Blot analysis of expression of gene PIA. Figure 5 sets forth the structure of gene PIA with its restriction sites. Figure 6 shows the results obtained when cells were transfected with the gene for PIA, either isolated from P815 or normal cells and then tested with CTL lysis. Figure 7 shows lytic studies using mast cell line L138. 8A. Figure 8 is a map of subfragments of the 2.4 kb antigen E fragment which also express the antigen. Figure 9 shows homology of sections of exon 3 from genes mage 1, 2 and 3. Figure 10 shows the result of Northern blots for MAGE genes on various tissues. Figure 11 presents the data of Figure 13 in table form. Figure 12 shows Southern Blot experiments using the various human melanoma cell lines employed in this application. Figure 13 is a generalized schematic of the expression of MAGE 1, 2 and 3 genes by tumor and normal tissues. Figure 14 shows results from a chromium release assay using CTL clone 20/38 on various cell lines. Figure 15 presents the result of assays undertaken to determine antigenic specificity of CTL clone 20/38. Figure 16 shows the results obtained when a TNF release assay was carried out on various transfected cells. Figure 17 shows results secured from qualitative PCR assays for MAGE-1 in lung adenocarcinomas. Figure 18 presents data pertaining to quantitative measurement of MAGE-1 expression in lung adenocarcinomas. Figure 19 shows reverse transcription/PCR amplification production of mRNA extracted from the bladder tumor of a patient referred to as "HM15". This is shown in all lanes marked "R". In lanes marked "D", amplification products of the genomic DNA from the patient are shown. Figure 20 displays the fraction of tumors expressing genes MAGE-1, 2, 3 and 4 among the superficial and invasive transitional cell carcinomas of the bladder. DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS Many different "MAGE" genes have been identified, as will be seen from the sequences which follow the application. The protocols described in the following examples were used to isolate these genes and cDNA sequences. "MAGE" as used herein refers to a nucleic acid sequence isolated from human cells. The acronym "smage" is used to describe sequences of murine origin. When "TRAP" or "TRAs" are discussed herein as being specific to a tumor type, this means that the molecule under consideration is associated with that type of tumor, although not necessarily to the exclusion of other tumor types. Example 1 In order to identify and isolate the gene coding for antigen P815A, gene transfection was used. This approach requires both a source of the gene, and a recipient cell line. Highly transfectable cell line Pl.HTR was the starting material for the recipient, but it could not be used without further treatment, as it presents "antigen A", one of four recognized P815 tumor antigens. See Van Pel et al., Molecular Genetics 11: 467-475 (1985). Thus, screening experiments were carried out to isolate cell lines which did not express the antigen and which nonetheless possessed Pl.HTR's desirable qualities. To do this, Pl.HTR was screened with CTLs which were specific for each of tumor antigens A, B, C and D. Such CTLs are described by Uyttenhove et al., J. Exp. Med. 157: 1040-1052 (1983) . To carry out the selection, 10 6 cells of Pl.HTR were mixed with 2-4xl0 6 cells of the CTL clone in a round bottom tube in 2 ml of medium, and centrifuged for three minutes at 150xg. After four hours at 37°C, the cells were washed and resuspended in 10 ml of medium, following Maryanski et al., Eur. J. Immunol. 12: 406-412 (1982). Additional information on the CTL assay and screening protocol, in general may be found in Boon et al., J. Exp. Med. 152: 1184-1193 (1980), and Maryanski et al., Eur. J. Immunol. 12: 406-412 (1982), the disclosures of which are incorporated by reference. When these selections were carried out, a cell line variant was found which expressed neither antigen A or B. Additional selections with CTLs specific for antigen C then yielded a variant which also lacked antigen C. Please see figure 2 for a summary of the results of these screenings. The variant PO.HTR is negative for antigens A, B and C, and was therefore chosen for the transfection experiments. The cell line PO.HTR has been deposited in accordance with the Budapest Treaty at the Institute Pasteur Collection Nationale De Cultures De Microorganismes, 28, Rue de Docteur Roux, 75724 Paris France, and has accession number 1-1117. This methodology is adaptable to secure other cell lines which are variants of a cell type which normally presents at least one of the four recognized P815 tumor antigens, i.e., antigens A, B, C and D, where the variants present none of antigens A, B and C. Pl.HTR is a astocytoma cell line, so it will be seen that the protocol enables the isolation of biologically pure mastocytoma cell lines which express none of P815 antigens A, B and C, but which are highly transfectable. Other tumor types may also be screened in this fashion to secure desired, biologically pure cell lines. The resulting cell lines should be at least as transfectable with foreign DNA as is Pl.HTR, and should be selected so as to not express a specific antigen. Example 2 Previous work reported by DePlaen et al., Proc. Natl. Acad. Sci. USA 85: 2274-2278 (1988) the disclosure of which is incorporated by reference herein had shown the efficacy of using cosmid library transfection to recover genes coding for turn" antigens. Selective plasmid and geno ic DNAs of Pl.HTR were prepared, following Wδlfel et al., Immunogenetics .26: 178- 187 (1987) . The transfection procedure followed Corsaro et al., Somatic Cell Molec. Genet 7: 603-616 (1981), with some modifications. Briefly, 60 μg of cellular DNA and 3 μg of DNA of plasmid pHMR272, described by Bernard et al., Exp. Cell. Biol. 158: 237-243 (1985) were mixed. This plasmid confers hygromycin resistance upon recipient cells, and therefore provides a convenient way to screen for transfectants. The mixed DNA was combined with 940 ul of 1 mM Tris-HCl (pH 7.5), 0.1 mM EDTA, and 310 ul 1M CaCl 2 . The solution was added slowly, and under constant agitation to 1.25 ml of 50 mM Hepes, 280 mM NaCl, 1.5 mM Na 2 HP0 4 , adjusted to pH 7.1 with NaOH. Calcium phosphate - DNA precipitates were allowed to form for 30-45 minutes at room temperature. Following this, fifteen groups of PO.HTR cells (5xl0 6 per group) were centrifuged for 10 minutes at 400xg. Supernatants were removed, and pellets were resuspended directly into the medium containing the DNA precipitates. This mixture was incubated for 20 minutes at 37°C, after which it was added to an 80 cm 2 tissue culture flask containing 22.5 ml DMEM, supplemented with 10% fetal calf serum. After 24 hours, medium was replaced. Forty- eight hours after transfection, cells were collected and counted. Transfected cells were selected in mass culture using culture medium supplemented with hygromycin B (350 ug/ml) . This treatment selected cells for hygromycin resistance. For each group, two flasks were prepared, each containing 8xl0 6 cells in 40 ml of medium. In order to estimate the number of transfectants, lxlO 6 cells from each group were plated in 5 ml DMEM with 10% fetal calf serum (FCS) , 0.4% bactoagar, and 300 ug/ml hygromycin B. The colonies were then counted 12 days later. Two independent determinations were carried out and the average taken. This was multiplied by 5 to estimate the number of transfectants in the corresponding group. Correction had to be made for the cloning efficiency of P815 cells, knowη to be about 0.3. Example 3 Eight days after transfection as described in example 2, supra. antibiotic resistant transfectants were separated from dead cells, using density centrifugation with Ficoll- Paque. These cells were maintained in non-selective medium for 1 or 2 days. The cells were plated in 96 well microplates (round bottom) , at 30 cells/microwell in 200 ul of culture medium. Anywhere from 100-400 microwells were prepared, depending on the number of transfectants prepared. Agar colony tests gave estimates of 500-3000. After 5 days, the wells contained about 6xl0 4 cells and replicate plates were prepared by transferring 1/10 of the wells to microplates which were then incubated at 30°C. One day later, master plates were centrifuged, medium removed, and 750 CTLs against P815 antigen A (CTL-PI:5) were added to each well together with 10 6 irradiated syngeneic feeder spleen cells in CTL culture medium containing 40 U/ml recombinant human IL-2, and HAT medium to kill stimulator cells. Six days later, plates were examined visually to identify wells where CTLs had proliferated. Where plates showed proliferating microcultures, aliquots of 100 ul of the wells were transferred to another plate containing 51 Cr labeled Pl.HTR target cells (2xl0 3 - 4xl0 3 per well) , and chromium release was measured after 4 hours. Replicate microcultures corresponding to those showing high CTL activity were expanded and cloned by limited dilution in DMEM with 10% FCS. Five days later, about 200 clones were collected and screened with the CTL.PI:5 cell line, described supra. in a visual lysis assay. See figure 1A for these results. In these experiments, three of the fifteen groups of transfectants yielded a few positive microcultures. These microcultures were tested for lytic activity against Pl.HTR, as described supra. Most of the microcultures where proliferation was observed showed lytic activity. This activity was well above background, as shown in figure IB. This figure summarizes data wherein two groups of cells (groups "5" and "14") , 400 and 300 microwells were seeded with 30 hygromycin resistant transfected cells. Amplification and duplication of the microcultures was followed by addition of anti-A CTL PI:5. Six days later, lytic activity against Pl.HTR was tested. In the figure, each point represents lytic activity of a single icroculture. Duplicate microcultures corresponding to several positive wells were subcloned, and more than 1% of the subclones were found to be lysed by anti-A CTL. Thus, three independent transfectants expressing P815A were obtained from 33,000 hygromycin resistant transfectants. One of these lines, referred to hereafter as P1A.T2 was tested further. The relevant antigen profile of P1A.T2 is shown in figure 2, this being obtained via anti-CTL assays of the type described supra. Example 4 The CTL assays carried out for P1A.T2 demonstrated that it presented antigen A ("P815A") , and therefore had received the gene from Pl.HTR. To that end, this cell line was used as a source for the gene for the antigen precursor in the following experiments. Prior work had shown that genes coding for turn" antigens could be recovered directly from transfectants obtained with a cosmid library. See DePlaen et al., Proc. Natl. Acad. Sci. USA 85: 2274-2278 (1988). This procedure was followed for recovery of the P815 gene. Total genomic DNA of P1A.T2 was partially digested with restriction endonuclease Sau 3A1, and fractionated by NaCl density gradient ultracentrifugation to enrich for 35- 50 kb DNA fragments, following Grosveld et al., Gene 10: 6715-6732 (1982) . These fragments were ligated to cosmid arms of C2RB, described by Bates et al., Gene 26: 137-146 (1983) , the disclosure of which is incorporated by reference. These cosmid arms had been obtained by cleavage with Smal and treatment with calf intestinal phosphatase, followed by digestion with BamHI. Ligated DNA was packaged into lambda phage components, and titrated on E. coli ED 8767, following Grosveld et al., supra. Approximately 9xl0 5 ampicillin resistant colonies were obtained per microgram of DNA insert. The cosmid groups were amplified by mixing 30,000 independent cosmids with 2 ml of ED 8767 in 10 mM MgCl 2 , incubated 20 minutes at 37°C, diluted with 20 ml of Luria Bertani ("LB") medium, followed by incubation for one hour. This suspension was titrated and used to inoculate 1 liter of LB medium in the presence of ampicillin (50 ug/ml) . At a bacterial concentration of 2xl0 8 cells/ml (00^ 0 =0.8), a 10 ml aliquot was frozen, and 200 ug/ml chloramphenicol was added to the culture for overnight incubation. Total cosmid DNA was isolated by alkaline lysis procedure, and purified on CsCl gradient. In these experiments, a library of 650,000 cosmids was prepared. The amplification protocol involved the use of 21 groups of approximately 30,000 cosmids. Example 5 Using the twenty-one groups of cosmids alluded to supra, (60 ug) and 4 ug of pHMR272, described supra. groups of 5xl0 6 PO.HTR cells were used as transfectant hosts. Transfection was carried out in the same manner as described in the preceding experiments. An average of 3000 transfectants per group were tested for antigen presentation, again using CTL assays as described. One group of cosmids repeatedly yielded positive transfectants, at a frequency of about 1/5,000 drug resistant transfectants. The transfectants, as with P1A.T2, also showed expression of both antigen A and B. The pattern of expression of transfectant P1A.TC3.1 is shown in figure 2, Example 6 As indicated in Example 5, supra, three independent cosmid transfected cells presenting P815A antigen were isolated. The DNA of these transfectants was isolated and packaged directly with lambda phage extracts, following DePlaen et al., Proc. Natl. Acad. Sci. USA 85: 2274-2278 (1988) . The resulting product was titrated on E. coli ED 8767 with ampicillin selection, as in Example 5. Similarly, amplification of the cosmids and transfection followed Example 5 , again using PO.HTR. High frequencies of transfection were observed, as described in Table 1 , which follows : Table 1. Transfer of the expression of antigen P815A by cosmids obtained by direct packaging Transfectant No. of cosmids obtained No. of transfectants obtained with by direct packaging of expressing P815A / no. the cosmid 0.5 μg of DNA of HmB r transfectants library TC3.1 32 87/192 TC3.2 32000 49/384 TC3.3 44 25/72 The cosmids were analyzed with restriction enzymes and it was found that directly packaged transfectant P1A.TC3.1 contained 32 cosmids, 7 of which were different. Each of these 7 cosmids was transfected into PO.HTR, in the manner described supra. and again, following the protocols described above, transfectants were studied for presentation of P815A. Four of the cosmid transfectants showed P815A presentation and, as with all experiments described herein, P815B was co-expressed. Of the four cosmids showing presentation of the two antigens, cosmid CIA.3.1 was only 16.7 kilobases long, and was selected for further analysis as described infra. The cosmid CIA.3.1 was subjected to restriction endonuclease analysis, yielding the map shown in Figure 3. All EcoRI fragments were transfected, again using the above described protocols, and only the 7.4 kilobase fragment produced a transfectant that anti-A CTLs could lyse. Similar experiments were carried out on the Pstl fragments, and only a 4.1 kb fragment fully contained within the 7.4 kb EcoRI fragment produced lysable transfectants. This fragment (i.e., the 4.1 kb Pstl fragment), was digested with Smal, giving a 2.3 kb fragment which also yielded host cells presenting antigens A and B after transfection. Finally, a fragment 900 bases long, secured with Smal/Xbal, also transferred expression of the precursors of these two antigens, i.e., the transfected host cell presented both antigen A and antigen B. Example 7 The 900 base fragment described above was used as a probe to detect the expression of the P815A gene in parent cell line Pl.HTR. To accomplish this, total cellular RNA was first isolated using the guanidine-isothiocyanate procedure of Davis et al. , Basic Methods In Molecular Biology (Elsevier Science Publishing Co, New York) (1986) . The same reference was the source of the method used to isolate and purify polyA + mRNA using oligodT cellulose column chromatography. Samples were then subjected to Northern Blot analysis. RNA samples were fractionated on 1% agarose gels containing 0.66 M formaldehyde. The gels were treated with lOxSSC (SSC: 0.15 M NaCl; 0.015 M sodium citrate, pH 7.0) for 30 minutes before overnight blotting on nitrocellulose membranes. These were baked for two hours at 80°C, after which the membranes were prehybridized for 15 minutes at 60°C in a solution containing 10% dextran sulfate, 1% SDS and 1M NaCl. Hybridization was then carried out using denatured probe (the 900 base fragment) , together with 100 ug/ml salmon sperm DNA. When this protocol was carried out using Pl.HTR poly A + RNA, a band of 1.2 kb and two fainter bands were identified, as shown in Figure 4, lane 1 (6 ug of the RNA). The same probe was used to screen a cDNA library, prepared from poly-A + RNA from the cell line. This yielded a clone with a lkb insert, suggesting a missing 5' end. The Northern blots for the cDNA are not shown. Hybridization experiments in each case were carried out overnight at 60°C. The blots were washed twice at room temperature with 2xSSC and twice at 60°C with 2xSSC supplemented with 1% SDS. The foregoing experiments delineated the DNA expressing the P815A antigen precursor sufficiently to allow sequencing, using the well known Sanger dideoxy chain termination method. This was carried out on clones generated using a variety of restriction endonucleases and by specific priming with synthetic oligonucleotide primers. The results for exons of the gene are set forth in SEQUENCE ID NO: 4. Example 8 The Northern analysis described supra suggested that the 5' end of the cDNA was missing. To obtain this sequence, cDNA was prepared from Pl.HTR RNA using a primer corresponding to positions 320-303. The sequence was then amplified using the polymerase chain reaction using a 3' primer corresponding to positions 286-266 and a 5' primer described by Frohman et al., Proc. Natl. Acad. Sci. USA 85: 8998-9002 (1988) . A band of the expected size (270 bases) was found, which hybridized to the 900 bp Smal/Xbal fragment described supra on a Southern blot. Following cloning into ml3tg 130 and tg 131, the small, 270 bp fragment was sequenced. The sequence is shown in SEQUENCE ID NO: 1. Example 9 Following the procurement of the sequences described in Examples 7 and 8 and depicted in SEQ ID NO: 4, a 5.7 kb region of cosmid CIA.3.1 was sequenced. This fragment was known to contain the 900 base fragment which expressed P815A in transfectants. This experiment permitted delineation of introns and exons, since the cosmid is genomic in origin. The delineated structure of the gene is shown in figure 5. Together with SEQ ID NO: 4, these data show that the gene for the antigen precursor, referred to as "PIA" hereafter, is approximately 5 kilobases long and contains 3 exons. An ORF for a protein of 224 amino acids starts in exon 1, ending in exon 2. The 900 base pair fragment which transfers expression of precursors for antigens A and B only contains exon 1. The promoter region contains a CAAT box, as indicated in SEQ ID NO: 1, and an enhancer sequence. This latter feature has been observed in promoters of most MHC class I genes, as observed by Geraghty et al., J. Exp. Med 171: 1-18 (1990); Kimura et al., Cell 44: 261-272 (1986). A computer homology search was carried out, using program FASTA with K-triple parameters of 3 and 6, as suggested by Lipman et al., Science 227: 1435-1441 (1985), and using Genbank database release 65 (October 1990) . No homology was found except for a stretch of 95 bases corresponding to part of an acid region coded by exon 1 (positions 524-618) , which is similar to sequences coding for acidic regions in mouse nucleolar protein N038/B23, as described by Bourbon et al., Mol. Biol. 200: 627-638 (1988), and Schmidt-Zachmann et al., Chromosoma 96: 417-426 (1988) . Fifty six of 95 bases were identical. In order to test whether these homologies were the reason for cross hybridizing, experiments were carried out using a mouse spleen cDNA library screened with the 900 base fragment. cDNA clones corresponding closely to the sizes of the cross hybridizing bands were obtained. These were partially sequenced, and the 2.6 kb cDNA was found to correspond exactly to reported cDNA sequence of mouse nucleolin, while the 1.5 kb cDNA corresponded to mouse nucleolar protein N038/B23. Analysis of the nucleotide sequence of the gene, referred to as "PIA" hereafter, suggests that its coded product has a molecular mass of 25 kd. Analysis of the SEQUENCE ID NO: 4 shows a potential nuclear targeting signal at residues 5-9 (Dingwall et al., Ann. Rev. Cell Biol. 2: 367-390 (1986)), as well as a large acidic domain at positions 83-118. As indicated supra. this contains the region of homology between PIA and the two nucleolar proteins. A putative phosphorylation site can be found at position 125 (serine) . Also, a second acidic domain is found close to the C-terminus as an uninterrupted stretch of 14 glutamate residues. A similar C-terminal structure has been found by Kessel et al. Proc. Natl. Acad. Sci. USA 84: 5306-5310 (1987), in a murine homeodomain protein having nuclear localization. In studies comparing the sequence of gene PIA to the sequences for P91A, P35B and P198, no similarities were found, showing that PIA is indicative of a different class of genes and antigens. Example 10 With the PIA probe and sequence in hand, investigations were carried out to determine whether the gene present in normal tissue was identical to that expressed by the tumor. To do this, phage libraries were prepared, using lambda zapll 10 and genomic DNA of DBA/2 murine kidney cells. PIA was used as a probe. Hybridization conditions were as described supra, and a hybridizing clone was found. The clone contained exons one and two of the PIA gene, and corresponded to positions -0.7 to 3.8 of figure 5. Following localization of this sequence, PCR amplification was carried out to obtain the sequence corresponding to 3.8 to 4.5 of figure 5. Sequence analysis was carried out, and no differences were found between the gene from normal kidneys and the PIA gene as obtained from the P815 tumor cells. In further experiments, the gene as found in DBA/2 kidney cells was transfected into PO.HTR, as described supra. These experiments, presented pictorially in figure 6, showed that antigens A and B were expressed as efficiently by the kidney gene isolated from normal P815 cells as with the PIA gene isolated from normal kidney cells. These experiments lead to the conclusion that the gene coding for the tumor rejection antigen precursor is a gene that does not result from a mutation; rather, it would appear that the gene is the same as one present in normal cells, but is not expressed therein. The ramifications of this finding are important, and are discussed infra. In studies not elaborated upon herein, it was found that variants of the gene were available. Some cells were "P1A " B + ", rather than the normal "PIA". The only difference between these is a point mutation in exon 1, with the 18th triplet coding for Ala in the variant instead of Val. Example 11 Additional experiments were carried out with other cell types. Following the protocols described for Northern blot hybridizations supra. RNA of normal liver and spleen cells was tested to determine if a transcript of the PIA gene could be found. The Northern blot data are presented in figure 4 and, as can be .seen, there is no evidence of expression. The murine P815 cell line from which PIA was isolated is a mastocytoma. Therefore, mast cell lines were studied to determine if they expressed the gene. Mast cell line MC/9, described by Nabel et al., Cell 23: 19-28 (1981), and short term cultures of bone marrow derived mast cells were tested in the manner described supra (Northern blotting) t but no transcript was found. In contrast when a BALB/C derived IL-3 dependent cell line L138.8A (Hϋltner et al., J. Immunol. 142: 3440-3446 (1989)) was tested, a strong signal was found. The mast cell work is shown in figure 4. It is known that both BALB/C and DBA/2 mice share H-2 d haplotype, and thus it was possible to test sensitivity to lysis using the CTLs described supra. Figure 7 shows these results, which essentially prove that anti-A and anti-B CTLs lysed the cells strongly, whereas anti-C and anti-D lines did not. Further tests were carried out on other murine tumor cell lines, i.e., teratocarcinoma cell line PCC4 (Boon et al., Proc. Natl. Acad. Sci. USA 74: 272-275 (1977), and leukemias LEC and WEHI-3B. Expression could not be detected in any of these samples. Example 12 The actual presentation of the PIA antigen by MHC molecules was of interest. To test this, cosmid CIA.3.1 was transfected into fibroblast cell line DAP, which shows phenotype H-2. The cell lines were transfected with genes expressing one of the K d , D d , and L d antigen. Following transfection with both the cosmid and the MHC gene, lysis with CTLs was studied, again as described supra. These studies, summarized in Table 2, show that L d is required for presentation of the PIA antigens A and B. Table 2. H-2-restriction of antigens P815A and P815B Recipient cell * No. of clones lysed by the CTL/no. of HmB' clones' * DAP (H-2 ) DAP + K d DAP + D d DAP + L d "cosmid CIA.3.1 containing the entire PIA gene was transfected in DAP cells previously transfected with H-2 d class I genes as indicated. ♦Independent drug-resistant colonies were tested by lysis by anti-A or anti-B CTL in a visual assay. The observation that one may associate presentation of a tumor rejection antigen with a particular MHC molecule was confirmed in experiments with human cells and HLA molecules, as elaborated upon infra. Example 13 Using the sequence of the PIA gene as well as the amino acid sequence derivable therefrom, antigenic peptides which were A + B + (i.e., characteristic of cells which express both the A and B antigens) , and those which are A"B + were identified. The peptide is presented in SEQ ID NO: 26. This peptide when administered to samples of PO.HTR cells in the presence of CTL cell lines specific to cells presenting it, led to lysis of the PO.HTR cells, lending support to the view that peptides based on the product expressed by the gene can be used as vaccines. Example 14 The human melanoma cell line referred to hereafter as MZ2-MEL is not a clonal cell line. It expresses four stable antigens recognized by autologous CTLs, known as antigens "D, E, F, and A". In addition, two other antigens "B" and "C" are expressed by some sublines of the tumor. CTL clones specific for these six antigens are described by Van den Eynde et al., Int. J. Cane. 44: 634-640 (1989). Among the recognized subclones of MZ2-MEL are MEL.43, MEL3.0 and MEL3.1. (Van den Eynde et al., supra) . Cell line MEL3.1 expresses antigen E, as determined by CTL studies as described for P815 variants, supra, so it was chosen as a source for the nucleic acid sequence expressing the antigen precursor. In isolating the pertinent nucleic acid molecule for a tumor rejection antigen precursor, the techniques developed supra, showed that a recipient cell is needed which fulfills two criteria: (i) the recipient cell must not express the TRAP of interest under normal conditions, and (ii) it must express the relevant class I HLA molecule. Also, the recipient cell must have a high transfection frequency, i.e., it must be a "good" recipient. In order to secure such a cell line, the clonal subline MEL3.1 was subjected to repeated selection with anti-E CTL 82/30 as described by Van den Eynde, supra. The repeated cycles of selection led to isolation of subclone MZ2-MEL-2.2 isc E " . This subclone is also HPRT", (i.e., sensitive to HAT medium: 10^ M hypoxanthine, 3.8 x 10" 7 aminopterine, 1.6 x 10 ~5 M 2-deoxythymidine) . The subclone is referred to as "MEL-2.2" for simplicity hereafter. Example 15 The genomic DNA of MEL3.0 was prepared following Wδlfel et al., Immunogenetics 26: 178-187 (1987), the disclosure of which is incorporated by reference. The plasmid pSVtkneoβ, as described by Nicolas et al., Cold Spring Harb. , Conf. Cell Prolif. 10: 469-485 (1983) confers geneticin resistance, so it can be used as a marker for cotransfection, as it was in this experiment. Following a procedure similar but not identical to that of Corsaro et al., Somatic Cell Molec. Genet 7: 603- 616 (1981) , total genomic DNA and the plasmid were cotransfected. The genomic DNA (60 μg) and plasmid DNA (6 μg) were mixed in 940 μl of 1 mM Tris-HCl (pH 7.5), 0.1 mM EDTA, after which 310 μl of 1M CaCl 2 was added. This solution was slowly added, under constant agitation, to 1.25 ml of 2xHBS (50 mM HEPES, 280 mM NaCl 1.5 mM Na 2 HP0 4 , adjusted to pH 7.1 with NaOH) . The calcium phosphate DNA precipitates were allowed to form for 30-45 minutes at room temperature, after which they were applied to 80 cm 2 tissue culture flasks which had been seeded 24 hours previously with 3xl0 6 MEL2.2 cells, in 22.5 ml of melanoma culture medium (Dulbecco's Modified Eagle's Medium) supplemented with 10% fetal calf serum. After 24 hours, the medium was replaced. Forty eight hours after transfection, the cells were harvested and seeded at 4xl0 6 cells per 80 cm 2 flask in melanoma culture medium supplemented with 2 mg/ml of geneticin. The geneticin serves as a selection marker. Example 16 Thirteen days after transfection, geneticin-resistant colonies were counted, harvested, and cultured in nonselective medium for 2 or 3 days. Transfected cells were then plated in 96-well microplates at 200 cells/well in 200 ul of culture medium with 20% fetal calf serum (FCS) in order to obtain approximately 30 growing colonies per well. The number of microcultures was aimed at achieving redundancy, i.e., such that every independent transfectant should be represented at least four times. After 10 days, wells contained approximately 6xl0 4 cells. These cells were detached, and 1/3 of each microculture was transferred to a duplicate plate. After 6 hours, i.e., after readherence, medium was removed and 1500 anti-E CTL (CTL 82/30) , were added to each well in 100 μl of CTL culture medium with 35 U/ml of IL-2. One day later, the supernatant (50 μl) was harvested and examined for TNF concentration, for reasons set forth in the following example. Example 17 The size of the mammalian genome is 6xl0 6 kb. As the average amount of DNA integrated in each drug-resistant transfectant was expected to be about 200 kb, a minimum of 30,000 transfectants would need to be examined to ascertain whether antigen E had been transfected. Prior work with murine cells had shown that when a CTL stimulation assay was used, groups containing only 3% of cells expressing the antigen of interested could be identified. This should reduce the number of assays by a factor of 30. While an anti-E CTL assay, as described supra, in mixed E + /E" cells was helpful, it was not sufficient in that consistent results could not be obtained. As a result, an alternative test was devised. Stimulation of CTLs was studied by release of tumor necrosis factor ("TNF") using well known methodologies which need not be repeated here. As described in Example 15, 1500 CTL 82/30 cells had been added per well of transfectants. These CTLs were collected 6 days after stimulation. As indicated supra, after 1/3 of the cells in each well had been removed and the remaining 2/3 (4xl0 4 ) had readhered, the CTLs and IL-2 were added thereto. The 50 μl of supernatant was removed 24 hours later and transferred to a microplate containing 3xl0 4 W13 (WEHI-164 clone 13; Espevik et al., J. Immunol. Meth. 95: 99-105 (1986)) cells in 50 μl of W13 culture medium (RPMI-1640, supplemented with L-arginine (116 mg/1) , L-asparagine (36 mg/1) , L- glutamine (216 mg/1) , and 10% FCS supplemented with 2 μg of actinomycin D at 37°C in an 8% C0 2 atmosphere. The cell line W13 is a mouse fibrosarcoma cell line sensitive to TNF. Dilutions of recombinant TNF-β in RPMI 1640 were added to target cell controls. The W13 cultures were evaluated after 20 hours of incubation, and dead cell percentage was measured using an adaptation of the colorimetric assay of Hansen et al., J. Immunol. Meth. 119: 203-210 (1989). This involved adding 50 ml of (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide at 2.5 mg/ml in PBS, followed by two hours of incubation at 37°C. Dark blue formazan crystals were dissolved by adding 100 μl of lysis solution (1 volume N,N dimethyl formamide mixed at 37°C with two volumes of water containing 30% (w/v) sodium dodecyl sulphate, at pH 4.7 from 1.6% acetic acid and 2.5% IN HC1) . Plates were incubated at 37°C overnight, and ODs were taken at 570 n using 650 nm as control. Dead cell percentage was determined via the formula: 100-(OD 570 sample well) 100 x 1 - ——---——--—-------—------—-- OD, n well + medium following Espevik et al., J. Immunol. Meth. 95: 99-105 (1986) . The results showed that even when the ratio of E + /E" cells was as low as 1/45, significant production of TNF was observed, thus showing active CTLs. This led to the decision to test the drug resistant transfectants in groups of 30. Example 18 Cells were tested for TNF production as discussed in Example 17, supra. A total of 100 groups of E " cells (4xl0 6 cells/group) were tested following transfection, and 7xl0 4 independent geneticin resistant transfectants were obtained, for an average of 700 per group. Only one group of transfected cells led to a microculture which caused anti-E antigen CTL clone 82/30 to produce TNF. Of 300 clones tested, 8 were positive. These clones were then tested for lysis by anti-E CTL, using the standard 51 Cr release assay, and were found to be lysed as efficiently as the original E + cell line. The transfectant E.T1, discussed herein,.had the same lysis pattern as did MEL2.2 for CTLs against antigens B,C,D and F. The fact that only one transfectant presented the antigen out of 70,000 geneticin resistance transfectants may at first seem very low, but it is not. The work described supra for P815 showed an average frequency of 1/13,000. Human DNA recipient MEL2.2 appears to integrate 5 times less DNA than Pl.HTR. Example 19 Once transfectant E.T1 was found, analysis had tq address several questions including whether an E + contaminant of the cell population was the cause. The analysis of antigen presentation, described supra, shows that E.T1 is B " and C " , just like the recipient cell MEL2.2. It was also found to be HPRT " , using standard selection procedures. All E + cells used in the work described herein, however, were HPRT + . It was also possible that an E + revertant of MEL2.2 was the source for E.T1. To test this, the observation by Perucho et al., Cell 22: 309-317 (1980), that cotransfected sequences usually integrate together at a single location of recipient genome was employed. If antigen E in a transfectant results from cotransfec-tion with pSVtkneoβ, then sequences should be linked and deletion of the antigen might also delete the neighboring pSVtkneoβ sequences. Wolfel et al., supra. has shown this to be true. If a normally E" cell is transfected with pSVtkneoβ, then sequences should be linked and deletion of the antigen might also delete the neighboring pSVtkneoβ sequences. If a normally E + cell transfected with pSVtkneoβ is E.T1, however, "co-deletion" should not take place. To test this, the transfectant E.T1 was subjected to immunoselection with 82/30, as described supra. Two antigen loss variants were obtained, which resisted lysis by this CTL. Neither of these had lost geneticin resistance; however, Southern blot analysis showed loss of several neo r sequences in the variants, showing close linkage between the E gene and neo r gene in E.T1, leading to the conclusion that E.T1 was a transfectant. Example 20 The E + subclone MZ2-MEL 43 was used as a source of DNA for preparation of a cosmid library. This library of nearly 700,000 cosmids was transfected into MZ2-MEL 2.2 cells, following the cosmid transfection protocols described supra. By packaging the DNA of cosmid transfectants directly into lambda phage components, it is sometimes possible to retrieve cosmids that contain the sequences of interest. This procedure was unsuccessful here, so rescue of the transfected sequence was accomplished by ligating DNA of the transfectant to appropriate restriction fragments of cosmid vector pTL6. This was tried with two transfectants and was successful with one of them. One cosmid, referred to as B3, was recovered from this experiment, and subjected to restriction endonuclease digestion via Xmal, or by BamHI digestion of a large, 12 kb Xmal transfected fragment. The fragments were cloned into vector pTZ 18R, and then transfected into MEL2.2. Again, TNF production was the measure by which successful transfection was determined. The experiments led to the determination of a gene sequence capable of transfecting antigen E on the 12 kb Xmal fragment, and then on the 2.4 kb fragment of BamHI digestion of the 12 kb segment. The 2.4 kb fragment hybridizes with a 2.4 kb fragment from MZ2-MEL and with a T cell clone of patient MZ-2, as determined by Southern Blots (BamHI digested DNA) . The band is absent from E " antigen loss variants of MZ2-MEL, as seen in SEQ ID NO: 7. The sequence for the E antigen precursor gene has been determined, and is presented herein: Example 21 After the 2.4 kb genomic segment had been identified, studies were carried out to determine if an "E + " subline expressed any homologous DNA. Cell line MZ2-MEL 3.0 was used as a source, and a cDNA library was prepared from its mRNA, using art known techniques. The 2.4 kb segment was used as a probe, and an mRNA of about 1.8 kb was identified as homologous, using Northern blot analysis. When cDNA was screened, clones were obtained showing almost complete identity to parts of the 2.4 kb fragment. Two exons were thus identified. An additional exon was located upstream of these, via sequencing segments of cosmid B3 located in front of the 2.4 kb BamHI fragment. The gene extends over about 4.5 kb, as shown in Figure 8. The starting point of the transcribed region was confirmed using PCR for the 5' end of the cDNA. The three exons comprise 65, 73, and 1551 base pairs. An ATG is located at position 66 of exon 3, followed by a 927 base pair reading frame. Example 22 To determine if smaller segments of the 2.4 kb fragment could transfer the expression of antigen E, smaller pieces corresponding to the larger gene were prepared, using art recognized techniques, and transferred into E" cells. Figure 8 shows the boundaries of the three segments. Transfer of antigen expression in this manner indicates that the gene codes for the antigen precursor, rather than coding for a protein which activates the antigen. Example 23 The probing of cDNA described supra revealed, surprisingly, two different but closely related cDNAs. These cDNAs, when tested, did not transfer expression of antigen E, but they do show substantial homology to the first cDNA segment. The three segments, appear to indicate a newly recognized family of genes, referred to as "MAGE" for "melanoma antigen". In Figure 9, MAGE-1" directs expression of the antigen from MZ2 cells. Portions of the third exon of each gene are presented in Figure 9. The second and third sequences are more closely related to each other than the first (18.1 and 18.9% difference compared to the first; 12% with each other) . Out of 9 cDNA clones obtained, three of each type were obtained, suggesting equal expression. "MAGE" as used hereafter refers to a family of molecules, and the nucleic acids coding for them. These nucleic acids share a certain degree of homology and are expressed in tumor cells including several types of human tumor cells as well as in human tumors. The family is referred to as "MAGE" because the first members were identified in human melanoma cells. As the experiments which follow indicate, however, the members of the MAGE family are not at all restricted to melanoma tumors; rather, MAGE refers to a family of tumor rejection antigen precursors and the nucleic acid sequences coding therefore. The antigens resulting therefrom are referred to herein as "MAGE TRAs" or "melanoma antigen tumor rejection antigens" Example 24 Experiments with mouse tumors have demonstrated that new antigens recognized by T cells can result from point mutations that modify active genes in a region that codes for the new antigenic peptide. New antigens can also arise from the activation of genes that are not expressed in most normal cells. To clarify this issue for antigen MZ2-E, the MAGE-1 gene present in the melanoma cells was compared to that present in normal cells of patient MZ2. Amplification by polymerase chain reaction (PCR) of DNA of phytohemagglutinin-activated blood lymphocytes using primers surrounding a 1300 bp stretch covering the first half of the 2.4 kb fragment was carried out. As expected, a PCR product was obtained whereas none was obtained with the DNA of the E " variant. The sequence of this PCR product proved identical to the corresponding sequence of the gene carried by the E + melanoma cells. Moreover, it was found that antigen MZ2-E was expressed by cells transfected with the cloned PCR product. This result suggests that the activation of a gene normally silent is responsible for the appearance of tumor rejection antigen MZ2-E. Example 25 In order to evaluate the expression of gene MAGE-1 by various normal and tumor cells, Northern blots were hybridized with a probe covering most of the third exon. In contrast with the result observed with human tumor cell line MZ2-MEL 3.0, no band was observed with RNA isolated from a CTL clone of patient MZ2 and phytohemagglutinin- activated blood lymphocytes of the same patient. Also negative were several normal tissues of other individuals (Figure 10 and Figure 11) . Fourteen melanoma cell lines of other patients were tested. Eleven were positive with bands of varying intensities. In addition to these cultured cell lines, four samples of melanoma tumor tissue were analyzed. Two samples, including a metastasis of patient MZ2, proved positive, excluding the possibility that expression of the gene represented a tissue culture artefact. A few tumors of other histological types, including lung tumors were tested. Most of these tumors were positive (Figures 10 and 11) . These results indicated that the MAGE gene family is expressed by many melanomas and also by other tumors. However, they provided no clear indication as to which of genes MAGE-1, 2 or 3 were expressed by these cells, because the DNA probes corresponding to the three genes cross-hybridized to a considerable extent. To render this analysis more specific, PCR amplification and hybridization with highly specific oligonucleotide probes were used. cDNAs were obtained and amplified by PCR using oligonucleotide primers corresponding to sequences of exon 3 that were identical for the three MAGE genes discussed herein. The PCR products were then tested for their ability to hybridize to three other oligonucleotides that showed complete specificity for one of the three genes (Figure 9) . Control experiments carried out by diluting RNA of melanoma MZ2-MEL 3.0 in RNA from negative cells indicated that under the conditions used herein the intensity of the signal decreased proportionally to the dilution and that positive signals could still be detected at a dilution of 1/300. The normal cells (lymphocytes) that were tested by PCR were confirmed to be negative for the expression of the three MAGE genes, suggesting therefore a level of expression of less than l/SOO" 1 that of the MZ2 melanoma cell line (Figure 11) . For the panel of melanoma cell lines, the results clearly showed that some melanomas expressed MAGE genes mage 1, 2 and 3 whereas other expressed only mage-2 and 3 (Figures 11 and 10) . Some of the other tumors also expressed all three genes whereas others expressed only MAGE-2 and 3 or only MAGE-3. It is impossible to exclude formally that some positive PCR results do not reflect the expression of one of the three characterized MAGE genes but that of yet another closely related gene that would share the sequence of the priming and hybridizing oligo¬ nucleotides. It can be concluded that the MAGE gene family is expressed by a large array of different tumors and that these genes are silent in the normal cells tested to this point. Example 26 The availability of a sequence that transfects at high efficiency and efficiently expresses a TRAP made it possible to search for the associated major histocompatibility complex (MHC) class I molecule. The class I specificities of patient MZ2 are HLA-A1, A29, B37, B44 and C6. Four other melanomas of patients that had Al in common with MZ2 were cotransfected with the 2.4 kb fragment and pSVtkneoβ. Three of them yielded neo r transfectants that stimulated TNF release by anti-E CTL clone 82/30, which is CD8+ (Figure 11) . No E- transfectant was obtained with four other melanomas, some of which shared A29, B44 or C6 with MZ2. This suggests that the presenting molecule for antigen MZ2-E is HLA-A1. In confirmation, it was found that, out of 6 melanoma cell lines derived from tumors of HLA-A1 patients, two stimulated TNF release by anti-E CTL clone 82/30 of patient MZ2. One of these tumor cell lines, MI13443-MEL, also showed high sensitivity to lysis by these anti-E CTL, These two melanomas were those that expressed MAGE-1 gene (Figure 11) . Eight melanomas of patients with HLA haplotypes that did not include Al were examined for their sensitivity to lysis and for their ability to stimulate TNF release by the CTL. None was found to be positive. The ability of some human anti-tumor CTL to lyse allogeneic tumors sharing an appropriate HLA specificity with the original tumor has been reported previously (Darrow, et al., J. Immunol. 142: 3329 (1989)). It is quite possible that antigenic peptides encoded by genes MAGE 2 and 3 can also be presented to autologous CTL by HLA-A1 or other class I molecules, especially in view of the similar results found with murine tumors, as elaborated upon supra. Example 27 As indicated supra. melanoma MZ2 expressed antigens F, D and A', in addition to antigen E. Following the isolation of the nucleic acid sequence coding for antigen E, similar experiments were carried out to isolate the nucleic acid sequence coding for antigen F. To do this, cultures of cell line MZ2-MEL2.2, an E " cell line described supra. were treated with anti-F CTL clone 76/6, in the same manner described for treatment with anti-E CTL clones. This resulted in the isolation of an F antigen loss variant, which was then subjected to several rounds of selection. The resulting cell line, "MZ2- MEL2.2.5" was completely resistant to lysis by anti-F CTLs, yet proved to be lysed by anti-D CTLs. Again, following the protocols set forth for isolation of antigen -E precursor DNA, the F " variant was transfected with genomic DNA from F + cell line MZ2-MEL3.0. The experiments yielded 90,000 drug resistant transfectants. These were tested for MZ2-F expression by using pools of 30 cells in the TNF detection assay elaborated upon supra. One pool stimulated TNF release by anti-F CTLs, and was cloned. Five of 145 clones were found to stimulate anti-F CTLs. Lysis assays, also following protocols described supra. confirmed (i) expression of the gene coding for antigen F, and (ii) presentation of antigen F itself. Example 28 Following identification of F + cell lines, the DNA therefrom was used to transfect cells. To do this, a cosmid library of F + cell line MZ2-MEL.43 was prepared. again using the protocols described supra. The library was divided into 14 groups of about 50,000 cosmids, and DNA from each group was transfected into MZ2-MEL2.2.5. Transfectants were then tested for their ability to stimulate TNF release from anti-F CTL clone 76/6. Of 14 groups of . cosmids, one produced two independent transfectants expressing antigen F; a yield of two positives out of 17,500 geniticin resistant transfectants. Example 29 The existence of a gene family was suggested by the pattern observed on the Southern blot (Figure 12) . To do this, the 2.4 kb BamHI fragment, which transferred the expression of antigen MZ2-E, was labelled with 32p and used as a probe on a Southern Blot of BamHI digested DNA of E + cloned subclone MZ2-MEL2.2. Hybridization conditions included 50 μl/cm 2 of 3.5xSSC, lxDenhardt's solution; 25 mM sodium phosphate buffer (pH 7.0), 0.5% SDS, 2mM EDTA, where the 2.4 kb probes had been labelled with [α 32 p]dCTP (2-3000 Ci/mole) , at 3xl0 6 cp /ml. Hybridization was carried out for 18 hours at 65°C. After this, the membranes were washed at 65°C four times for one hour each in 2xSSC, 0.1% SDS, and finally for 30 minutes in O.lxSSC, 0.1% SDS. To identify hybridization, membranes were autoradiographed using Kodak X-AR film and Kodak X-Omatic fine intensifying screens. In the following examples, whenever "hybridization" is referred to, the stringency conditions used were similar to those described supra. "Stringent conditions" as used herein thus refers to the foregoing conditions; subject tp routine, art recognized modification. Example 30 The cDNA coding for MAGE 4 was identified from a sample of the human sarcoma cell line LB23-SAR. This cell line was found to not express MAGE 1, 2 or 3, but the mRNA of the cell line did hybridize to the 2.4 kb sequence for MAGE 1. To study this further, a cDNA library was prepared from total LB23-SAR mRNA, and was then hybridized to the 2.4 kb fragment. A cDNA sequence was identified as hybridizing to this probe, and is identified hereafter as MAGE 4. Example 31 Experiments were carried out using PHA-activated lymphocytes from patient "MZ2", the source of the "MZ" cells discussed supra. An oligonucleotide probe which showed homology to MAGE 1 but not MAGE 2 or 3 was hybridized with a cosmid library derived from the PHA activated cells. The size of the hybridizing BamHI cosmid fragment, however, was 4.5 kb, thus indicating that the material was not mage 1; however, on the basis of homology to mage 1-4, the fragment can be referred to as "MAGE 5". The sequence of MAGE 5 is presented in SEQ ID NO: 16. Example 32 Melanoma cell line LB-33-MEL was tested. Total mRNA from the cell line was used to prepare cDNA, which was then amplified with oligos CH09: (ACTCAGCTCCTCCCAGATTT) (SEQ ID NO: 53), and CHO10: (GAAGAGGAGGGGCCAAG) (SEQ ID NO: 54). These oligos correspond to regions of exon 3 that are common to previously described mage 1, 2 and 3. To do this, 1 μg of RNA was diluted to a total volume of 20 μl, using 2 μl of lOx PCR buffer, 2 μl of each of 10 mM dNTP, 1.2 μl of 25 mM MgCl 2 , 1 μl of an 80 mM solution of CH09, described supra. 20 units of RNAsin, and 200 units of M-MLV reverse transcriptase. This was followed by incubation for 40 minutes at 42°C. PCR amplification followed, using 8 μl of lOx PCR buffer, 4.8 μl of 25 mM MgCl 2 , 1 μl of CHO10, 2.5 units of Thermus acquaticus ("Taq") polymerase, and water to a total volume of 100 μl. Amplification was then carried out for 30 cycles (l minute 94°C; 2 minutes at 52°C, 3 minutes at 72°C) . Ten μl of each reaction were then size fractionated on agarose gel. followed by nitrocellulose blotting. The product was found to hybridize with oligonucleotide probe CH018 (TCTTGTATCCTGGAGTCC) (SEQ ID NO: 55) . This probe identified mage 1 but not mage 2 or 3. However, the product did not hybridize to probe SEQ 4 (TTGCCAAGATCTCAGGAA) (SEQ ID NO: 56) . This probe also binds mage 1 but not 2 and 3. This indicated that the PCR product contained a sequence that differed from MAGE 1, 2 and 3. Sequencing of this fragment also indicated differences with respect to MAGE 4 and 5. These results indicate a sequence differing from previously identified MAGE 1, 2, 3, 4 and 5, and is named MAGE 6. Example 33 In additional experiments using cosmid libraries from PHA-activated lymphocytes of MZ2, the 2.4 kb MAGE 1 fragment was used as a probe and isolated a complementary fragment. This clone, however, did not bind to oligonucleotides specific for MAGE 1, 2, 3 or 4. The sequence obtained shows some homology to exon 3 of mage 1, and differs from MAGES 1-6. It is referred to as mage 7 hereafter. Additional screenings yielded MAGE 8-11. All MAGE sequences identified are presented as SEQ ID's. Example 34 The usefulness of the TRAPS, as well as TRAs derived therefrom, was exemplified by the following. Exon 3 of MAGE 1 was shown to transfer expression of antigen E. As a result, it was decided to test whether synthetic peptides derived from this exon 3 could be used to confer sensitivity to anti-E CTL. To do this, and using standard protocols, cells normally insensitive to anti-E/CTLs were incubated with the synthetic peptides derived from Exon 3.1. Using the CTL lytic assays described supra on P815A, and a peptide concentration of 3 mM, the peptide Glu-Ala-Asp-Pro-Thr-Gly- His-Ser-Tyr (SEQ ID NO: 26) was shown to be best. The assay showed lysis of 30%, indicating conferring of sensitivity to the anti-E CTL. Example 35 Nucleic acid sequences referred to as "sraage" were isolated from murine cells. Using the protocols described supra. a cosmid library was prepared from the DNA of normal DBA/2 kidney cells, using cosmid vector C2RB. As a probe, the 2.4 kb BamHI fragment of MAGE-1 was used. The DNA was blotted to nylon filters, and these were washed in 2xSSC at 65°C to identify the smage material. Example 36 Further tissue samples were tested for the presence of MAGE genes, using the protocols discussed supra. Some of these results follow. There was no expression of the MAGE genes in brain or kidney tumor tissue. Colon tumor tissue showed expression of MAGE 1, 2, 3 and 4, although not all tumors tested showed expression of all MAGE genes. This is also true for pancreatic tumor (MAGE 1); non-small cell lung (MAGE 1, 2, 3 and 4), prostate (MAGE 1), sarcomas (MAGE 1, 2, 3 and 4), breast (MAGE 1, 2 and 3), and larynx (MAGE 1 and 4). Example 37 A cytolytic CTL clone "20/38" was obtained from peripheral blood lymphocytes of melanoma patient MZ2. This clone is described by Van den Eynde et al., Int. J. Cancer 44: 634-640 (1989), the disclosure of which is incorporated by reference. The CTL clone was isolated following Herin et al., Int. J. Cancer 39: 390-396 (1987), which is incorporated by reference. The assay is described herein, however. Autologous melanoma cells were grown in vitro, and then resuspended at 10 7 cells/ml in DMEM, supplemented with 10% HEPES and 30 mM FCS, and incubated for 45 minutes at 37°C with 200 μCi/ml of Na( 51 Cr)0 4 . Labelled cells were washed three times with DMEM, supplemented with 10 mM HEPES. These were then resuspended in DMEM supplemented with 10 mM HEPES and 10% FCS, after which 100 μl aliquots containing 10 3 cells, were distributed into 96 well microplates. Samples of the CTL clone were added in 100 ul of the same medium, and assays were carried out in duplicate. Plates were centrifuged for four minutes at lOOg, and incubated for four hours at 37°C in a 5.5% C0 2 atmosphere. Plates were centrifuged again, and 100 ul aliquots of supernatant were collected and counted. Percentage of 51 Cr release was calculated as follows: % 51 Cr release = (ER-SR) x 100 (MR-SR) where ER is observed, experimental 51 Cr release, SR is spontaneous release measured by incubating 10 3 labeled cells in 200 ul of medium alone, and MR is maximum release, obtained by adding 100 ul 0.3% Triton X-100 to target cells. Those mononuclear blood samples which showed high CTL activity were expanded and cloned via limiting dilution, and were screened again, using the same methodology. The same method was used to test target K562 cells. When EBV-B cells were used, the only change was the replacement of DMEM medium by Hank's medium, supplemented with 5% FCS. These experiments led to isolation of CTL clone 20/38. Figure 14 presents the results of these assays. Specifically, it will be seen that the CTL clone lysed autologous melanoma cell line MZ2-MEL.3.0, but did not lyse EBV-B cell lines, fibroblasts, K562 or non-autologous melanoma cell line SK-MEL-29. Example 38 Once the CTL clone was recognized as being specific for the autologous cell line, it was tested for antigenic specificity. To do this, antigen loss variants derived from melanoma cell line MEL-MZ2 were tested in the same type of chromium release assay described above. These target lines were MZ2-MEL 3.0, which is D + , E + , F + , A + , MZ2- MEL.61, which is D ' , MZ2-MEL 2.2, which is E " , and MZ2-MEL.4, which is F'. In addition to CTL clone 20/38, clones which are known to be anti-A (CTL 28/336) , anti-F (CTL 76/6) , and anti-E (CTL 22/13) were tested. These results are set forth in figure 15. It will be seen that CTL clone 20/38 lysed all the cell lines leading to chromium release except D " cell line MZ2-MEL.61, thus indicating that the CTL clone is anti-D. This result was confirmed, in experiments not included herein, by experiments where TNF release by the CTL clone was observed only in the presence of melanoma lines presenting antigen D. Example 39 Once antigen D was identified as the target molecule, studies were carried out to determine the HLA type which presented it. The experiments described in example 38 showed that antigen D was presented by MZ2-MEL, and this cell line's HLA specificity is known (i.e., Al, A29, B37, B44, Cw6, C.cl.10). It was also known, however, that a variant of MZ2-MEL which had lost HLA molecules A29, B44 and C.cl.10 still expressed antigen D, so these could be eliminated from consideration. Studies were not carried out on lines expressing B37, as none could be found. In all, 13 allogeneic lines were tested, which expressed either HLA-A1 (10 of 13), or Cw6 (3 of 13). Thβ cell lines were tested for their ability to stimulate release of TNF by CTL clone 20/38, using the method of Traversari et al., Immunogenetics 35: 145-152 (1992), the disclosure of which is incorporated by reference. This assay measures TNF release via testing toxicity of supernatants on WEHI 164-13 cells. In the assays, cell samples (3000, 10,000 or 30,000 cells) from the allogeneic lines were cultured in the presence of 1500 cells of the CTL clone, and 25 u/ml of IL- 2. Twenty-four hours later, the supernatant from the culture was tested against the WEHI cells for toxicity. The results are presented in Table 3, which follows. Eight cell lines were found to stimulate TNF release from the CTL clone 20/38. All of these lines were HLA-Al. None of the Cw6 presenting lines did so. The cell lines were also assayed to determine MAGE expression. All eight of the lines which stimulated TNF release expressed MAGE-3, whereas the two HLA-Al lines which were negative did not. 41 2abl£_2 Expression Expression Melanoma TNF pp /ml of Maue-3 of HLΑ-ft-1 15DD CTL 20/38 and 25μ/ml IL2 were mixed with the indicated number of cells cf the different allogeneic melanomas. 24 hours later, the amount of TNF present in the supernatant was assayed by testing its jrytotoxicity for VEE2-164-13 cells. Example 0 In view of the results set forth in example 39, experiments were carried out to determine if antigen D was in fact a tumor rejection antigen derived from MAGE-3. To do this, recipient COS-7 cells were transfected with lOOng of the gene for HLA-Al cloned into pcDNA I/Amp, and 100 ng of one of (a) cDNA for MAGE-1 cloned into pcDNA I/Amp, (b) cDNA for MAGE-2 cloned into pcDSRα, or (c) cDNA for MAGE-3 cloned into pcDSRα. The transfecting sequences were ligated into the plasmids in accordance with manufacturer's instructions. Samples of COS-7 cells were seeded, at 15,000 cells/well into tissue culture flat bottom microwells, in Dulbeco's modified Eagles Medium ("DMEM") supplemented with 10% fetal calf serum. The cells were incubated overnight at 37°C, medium was removed and then replaced by 30 μl/well of DMEM medium containing 10% Nu serum, 400 μg/ml DEAE-dextran, 100 μM chloroquine, and the plasmids described above. Following four hours of incubation at 37°C, the medium was removed, and replaced by 50 μl of PBS containing 10% DMSO. This medium was removed after two minutes and replaced by 200 μl of DMEM supplemented with 10% of FCS. Following this change in medium, COS cells were incubated for 24 hours at 37°C. Medium was then discarded, and 1500 cells of CTL clone 20/38 were added, in 100 μl of Iscove's medium containing 10% pooled human serum, supplemented with 25 u/ml of IL-2. Supernatant was removed after 24 hours, and TNF content was determined in an assay on WEHI cells, as described by Traversari et al., Immunogenetics 35: 145-152 (1992), the disclosure of which is incorporated by reference. These results are shown in figure 16. It will be seen that the CTL clone was strongly stimulated by COS-7 cells transfected with HLA-Al and MAGE- 3, but not by the cells transfected with the other Mage genes. This leads to the conclusion that antigen D is a tumor rejection antigen derived from the tumor rejection antigen precursor coded by gene MAGE-3, and that this TRA is presented by HLA-Al molecules. Example 41 It is well known that different alleles of genes may produce different proteins. This principle should extend to the MAGE family of genes as well, and is an important consideration in view of diagnostic and therapeutic ramifications. Thus, polymorphism in the MAGE family was studied. To address the issue of polymorphism, blood lymphocytes of ten individuals were collected, and genomic DNA extracted. This DNA was subjected to Southern blotting in accordance with James et al.. Cane. Res. 48: 5546-5551 (1988) , incorporated by reference. Briefly, the labelled 2.4 kb genomic DNA fragment of MAGE-1, containing the last two exons of MAGE-1, described supra, was hybridized with the filter carrying the digested DNA, at 42°C for at least 16 hours, in 50% formamide, 5% dextran sulfate, 6xSSC, 1% SDS and 0.1 mg/ml heterologous DNA. The hybridization filters were washed, consecutively, in 2xSSC, 0.1% SDS (room temperature, 15 minutes), and twice in O.lxSSC, 0.1% SDS at 67°C for 30 minutes, each wash. Autoradiography was carried out at -70°C for 7-10 days, using standard film. A pattern of 13 hybridizing bands was observed, which was conserved over all individuals. One individual did show an additional band, but also showed the 13 band pattern. Example 42 It was of interest to determine which chromosome or chromosomes bear the MAGE genes. To ascertain this, a panel of hamster/human somatic cell hybrids was used. The hybrids were obtained either from the Human Genetic Mutant Cell Repository ("GM" prefix) , or from Johns Hopkins University ("A 3 " prefix) . Each hybrid was cytogenetically studied to determine human chromosome content. Total genomic DNA of the hybrids was probed in the same manner described in Example 41, supra (the conditions of stringency used prevented cross hybridization with hamster DNA) . Table 4, which follows, summarizes the result of the probe work. . Analysis of the data led to the conclusion that the pattern of hybridization was only concordant with location of MAGE-1 on the X chromosome. TABLE 4 - Segregation of MAGE-1 with human chrαmos nes in human-hamster hybrid cell DNA Hybrid MACE- 1 Human chromosome 1 2 3 5 6 7 8 9 10 II 12 13 14 15 16 17 18 19 20 21 22 X Y + + - + - + - + 1 c: + + + + + - + + + + + + + + + + + + + + + + + + + + + ± + + - + + 6 + + + - ± ± + + + + + + - - + _ + + + + - - _ + 2 1 3 2 1 3 4 2 1 3 4 3 3 3 0 3 1 2 1 3 1 8 4 17 19 14 14 15 18 16 17 18 17 17 16 14 18 17 17 19 18 16 14 15 18 17 7 3 6 7 5 4 6 4 2 2 1 5 0 3 Percent discordancy 22 23 38 37 41 24 22 23 30 30 26 22 30 37 16 33 26 27 23 35 37 36 0 26 + = chromosome present; - = chromosome absent; ± = very faint bands, indicating that only a, small percentage of the cells contained the chromosome (not included in calculation of percent discordancy 1,2 - GM09142 contains only part of chromosomes X and 21, der 21 1(X;21) (p2l;pl2) 3,4 - GM10095 contains only part of chromosomes X and 9, der 9 1(X;9) 5 - PgMe4 contains a deleted chromosome 2 andismissing 2p23-p24 6 - A 3 G1 contains only the q arm of chromosome 6 Example 43 In this experiment, a study was carried out to determine if all twelve known MAGE genes were located on the X chromosome. This was accomplished via the use of polymerase chain reaction ("PCR") technology. RNA purification and cDNA synthesis were first carried out, in accordance with Weynants et al., Int. J. Cancer 56: 826-829 (1994), incorporated by reference herein. Next, 1/20 of the cDNA produced from 2 ug of total RNA was supplemented with 5 ul of PCR buffer (500 mM KCl, 100 mM Tris pH 8.3) , 1 ul each of 10 mM dNTPs, 25 pmoles of each primer (see below), 3 ul of 25 mM MgCl 2 , and 1.25 units of Taq polymerase, with water added to final volume of 50 ul. The primers were as follows: MAGE-3: 5'-TGGAGGACCAGAGGCCCCC, 5'-GGACGATTATCAGGAGGCCTGC (725 bp) (SEQ ID NOS: 27 AND 28) MAGE-4: 5'-GAGCAGACAGGCCAACCG, 5'-AAGGACTCTGCGTCAGGC (446 bp) (SEQ ID NOS; 29 AND 30) MAGE-5: 5'CTAGAGGAGCACCAAAGGAGAAG, 5'-TGCTCGGAACACAGACTCTGG (413 bp) (SEQ ID NOS: 31 AND 32) MAGE-6: 5'-TGGAGGACCAGAGGCCCCC, 5'-CAGGATGATTATCAGGAAGCCTGT (727 bp) (SEQ ID NOS: 33 AND 34) MAGE-7: 5'-CAGAGGAGCACCGAAGGAGA , 5'-CAGGTGAGCGGGGTGTGTC (405 bp) (SEQ ID NOS: 35 AND 36) MAGE-8: 5'-CCCCAGAGAAGCACTGAAGAAG, 5'-GGTGAGCTGGGTCCGGG (399 bp) (SEQ ID NOS: 37 AND 38) MAGE-9: 5'-CCCCAGAGCAGCACTGACG, 5'-CAGCTGAGCTGGGTCGACC (391 bp) (SEQ ID NOS: 39 AND 40) MAGE-10: 5'-CACAGAGCAGCACTGAAGGAG, 5'-CTGGGTAAAGACTCACTGTCTGG (485 bp) (SEQ ID NOS: 41 AND 42) MAGE-11: 5'-GAGAACCCAGAGGATCACTGGA, 5'-GGGAAAAGGACTCAGGGTCTATC (422 bp) (SEQ ID NOS: 43 AND 44) MAGE-12: 5'-GGTGGAAGTGGTCCGCATCG, 5'-GCCCTCCACTGATCTTTAGCAA (392 bp) (SEQ ID NOS: 45 AND 46) Amplification was carried out for 30 cycles (MAGE-3, 4, 6, 12) or 32 cycles (MAGE-5, 7-11), where a cycle was one minute at 94°C followed by two minutes at 65°C for MAGE-5, 7-12, or two minutes at 68°C (MAGE-4), or two minutes at 71°C (MAGE-3 and MAGE-6); followed by three minutes at 72°C (MAGE-3, 5-12), or two minutes at 72°C (MAGE-4). The analysis was carried out on hybrid cell line GM 10868, which contains human chromosome 12, and GM 07301, which contains chromosome 12 and the X- chromosome. All assays were negative with the human GM 10868 line, and all were positive with the GM 07301 cell line, which indicated that all 12 genes are found on the X-chromosome. Example 44 The sizes of mRNAs for the different MAGE genes are similar, and thus Northern blot analysis cannot be used to determine expression of the various MAGE genes in different tissues, both normal and tumor. PCR analysis, along the lines of the study in example 43, supra. however, was believed to be useful. To this end, a series of various tumors and normal tissues were tested for expression of MAGE genes. Total RNA of the cells tested was extracted, and was then oligo dT primed, following art known techniques. The resulting' aterial was then subjected to PCR, following the protocols of example 43, supra. For MAGE-1 and MAGE-2, the protocols of Brasseur et al., Int. J. Cancer. 52: 839-841 (1992), and DeSmet et al., Immunogenetics 39: 121-120 (1994), both of which are incorporated by reference, were used. Table 5, which follows, elaborates these results, with a representative but by no means exhaustive listing of tissues tested. Each of MAGE 1-4, 6 and 12 showed significant expression in a number of tumors of varied tissue types. MAGE-5 and 8-11 were expressed very weakly in all tissues tested, whereas MAGE-7 RNA was not detectable at all. With respect to normal tissues, including tissues taken from a >20 week fetus, all were negative for MAGE RNA but for testis and placenta. Testis expressed all MAGE genes but MAGE-7, while placenta expressed MAGE-3, 4, and 8-11. TABLE 5. Expression of Mage-1, 2, 3, 4, 6 and -12 by tumors and normal tissues MAGE 1 MAGE 2 MAGE 3 MAGE 4 MAGE 6 MAGE 12 COLON CARCINOMAS MZ-CO-2 U ++ ++ SK-CO-11 _ LB150 - HSR 320 f LEUKEMIAS K562 _ MELANOMAS MI10221 . M22-MEL 3.0 1 . +++ +++ +++ - +++ + LB265 " ++ - + LG7 " . ++ . . - . LG11 " ++ ++ LB271 " - ++ LUNG CANCERS LB178 (NSCLC) ** ++ L3175 (NSCLC) ~ - ++ +++ +++ - +++ LE11 (SCLC) 1 ++ +++ -H-+ - - +++ LB12 (SCLC) 1 - +++ SARCOMAS LB23 1 - - LB408 " - LB258 ** . + ++ BREAST CARCINOMAS LB280 " ++ LS284 * * ++ ++ Stomach - Lung - Breast - Colon - Skin - Uterus -. -. _ . Testis ++ ++ ++ ++ Thymocytes -■ EBV-lymphocytes - Foetal liver - -. - -. Foetal brain Placenta LB694 + +++ RNA from tumor cell lines (~), tumor samples ( * ") and normal tissues were tested by RT-PCR for the expression of MAGE genes. PCR primers were chosen as indicated in methods. For MAGE-12, PCR amplification of RNA in the absence of reverse transcription indicated that in our conditions the contamination by genomic DNA was negligible. The level of expression evaluated by band intensity of PCR products fractionated in agarose gels is represented by +++, ++, +. Absence of product is indicated by -. Example 5 The expression of the MAGE-1, 2 and 3 genes in various tumors and normal tissues was evaluated, using both reverse transcription and polymerase chain reaction ("PCR") amplification. To perform these assays, the total RNA of the cells of interest was extracted via the well known guanidine-isothiocyanate procedure of Davis et al., Basic Methods in Molecular Biology, 1986 (New York, Elsevier, pp. 130) , which is incorporated by reference in its entirety. cDNA was then synthesized, by taking 2 ug of the RNA, diluting it with water, and then adding the following materials: 4 ul of 5X reverse transcriptase buffer, 1 ul each of each dNTP (10 mM) , 1 ul of a 40 μM solution of oligo dT(15) , 20 units of RNAsin, 2 ul of 0.1 M dithiothreitol, and 200 units of MoMLV reverse transcriptase. All materials were mixed in a 20 ul reaction volume, and incubated at 42°C for 60 minutes and diluted to 100 ul with water. Presence or absence of each of MAGE-1, -2, and -3 cDNA was detected via PCR amplification, in separate reactions, using oligonucleotide primers located in different exons of the MAGE gene of interest. For MAGE-1, the primers were: 5'-CGGCCGAAGGAACCTGACCCAG-3' (SEQ ID NO: 47) 5'-GCTGGAACCCTCACTGGGTTGCC-3' (SEQ ID NO: 48) These are described by Brasseur et al., Int. J. Cancer 52: 839-841 (1992). For MAGE-2, the primers were: 5'-AAGTAGGACCCGAGGCACTG-3' (SEQ ID NO: 49) 5'-GAAGAGGAAGAAGCGGTCTG-3' (SEQ ID NO: 50) (DeSmet et al., Immunogenetics 39: 121-129 (1994)). For MAGE-3, the primers were: 5'-TGGAGGACCAGAGGCCCCC-3' (SEQ ID NO: 27) 5'-GGACGATTATCAGGAGGCCTGC-3' (SEQ ID NO: 28) (Serial No. 08/204,727 filed March 1, 1994 to Gaugler et al. incorporated by reference) . For each PCR reaction, 5 ul of cDNA were supplemented with 5 ul of 10XPCR buffer, 1 ul of each dNTP (10 mM) , 1 ul each of 40 μM primer solutions, 1.25 units of Taq polymerase, and water, to a total volume of 50 ul. Each mixture was heated for five minutes at 94°C. Amplification was then carried out for 30 cycles (MAGE-1: 1 minute at 94°C, 3 minutes at 72°C; MAGE-2: 1 minute at 94°C, 2 minutes at 67°C; MAGE-3: 1 minute at 94°C, 4 minutes at 72°C) . Cycling was concluded, in each case, with a final extension at 72°C for 15 minutes. A 10 ul sample of each reaction was run on a 1% agarose gel, and visualized by ethidium bromide fluorescence. To ensure that RNA was not degraded, a PCR assay with primers specific for β-actin was carried out, following the listed protocols, except that only 20 cycles were carried out with the annealing step at 65°C. Date are summarized in the Table which follows: Table 6 Expression of gene MAGE-1, 2 and 3 in lung tumors Proportion of positive samples MAGE-1 MAGE-2 MAGE-3 Non-small cell lung cancer 1 6/46 16/46 14/46 Small cell cancer 1/3 2/3 2/3 Normal lung samples 0/8 0/8 0/8 Example 6 The previous example showed how to identify expression of various MAGE genes. This example explains quantitation of the expression. First, cDNA was synthesized in the same way described in example 1, except that the oligo dT consisted solely of dT15, and the reaction mixture was preincubated at room temperature for 10 minutes to optimize annealing. Also, following the incubation, the transcriptase activity was terminated by heating the mixture at 95°C for 15 minutes.* PCR amplification was carried out, by combining 5 ul of lOx PCR buffer, 0.5 ul of a 2.5 mM dNTP mix, 0.2 μCi of α 3 P- dCTP, 0.5 ul of each primer (40 μM solution), 1.25 units of Taq polymerase, and water, to a total of 50 ul. The mixtures were chilled on ice, and then 5 ul of chilled cDNA solution (100 ng total RNA) were added thereto. The mixture was heated to 94°C for five minutes, and 24 cycles of amplification were carried out (one minute at 94°C, three minutes at 72°C per cycle) . Cycling concluded with a final extension at 72°C, for 15 minutes. A 15 ul sample of PCR product was run on an agarose gel which was then fixed in 10% trichloroacetic acid for 30 minutes, dried, and then exposed to a phospho-screen for 90 minutes before scanning by Phosphor-Imager to measure incorporated 32 P. This was compared to the incorporations from various dilutions of RNA of reference melanoma cell line MZ2-MEL- 3.0. Quantitative measurements of β-actin messenger and "GAPDH" (i.e., glyceraldehyde 3-phosphate dehydrogenase) was carried out on each cDNA sample, under similar conditions. The one difference was that only 18 amplification cycles were carried out. A separate PCR reaction was set up with primers for β-actin and GAPDH, with only β-actin used for normalization. Results were expressed via formula: MAGE-l-S Actin-S 100 x MAGE-1-MEL Actin-MEL where: S = product from tumor sample MEL = product from MZ2-MEL 3.0 The results obtained were comparable to those obtained previously with melanoma tumors. Level of expression varied, from 1 to 160% of the amount expressed by the reference cell line. Figure 2 presents some of these results (i.e., normalized results, relative to levels of β- actin expression) . Values are percent of the level of MAGE-1 expression measured with RNA of the reference line MZ2-MEL-3.0. Values are for MAGE-1 positive tumors of Table 2). Table 7, which follows, summarizes patterns of expression for various tumors. Table 7. Pattern of expression of genes MAGE-1 ,2 and 3 by MAGE-positive lung tumor samples LB 498 (A1) +++ LB 557 +++ +++ Adenocarcinoma LB 117 (A1) LB 212 LB 264 (A1) LB 292 LB 306 LB 322 LB 474 (A1) LB 497 LB 510 LB 558 (A1) Large cell carcinoma LB 259 Small cell lung cancer LB 444 ++ +++ LB 648 (A1) ++ +++ Example 47 The expression of the MAGE-3 gene in various tumors and normal tissues was evaluated, using both reverse transcription and polymerase chain reaction ("PCR") amplification. To perform these assays, the total RNA of the cells of interest was extracted via the well known guanidine-isothiocyanate procedure of Davis et al., Basic Methods in Molecular Biology, 1986 (New York, Elsevier, pp. 130) , which is incorporated by reference in its entirety. cDNA was then synthesized, by taking 2 ug of the RNA, diluting it with water, and then adding the following materials: 4 ul of 5X reverse transcriptase buffer, 1 ul each of each dNTP (10 mM) , 2 ul of a 20 μM solution of oligo dT, 20 units of RNAsin, 2 ul of 0.1 M dithiothreitol, and 200 units of MoMLV reverse transcriptase. All materials were mixed in a 20 ul reaction volume, and incubated at 42°C for 60 minutes. For the amplification reaction, 1/20 of the cDNA reaction product was supplemented with 5 ul of PCR buffer, 0.5 ul of each of the dNTPs (10 mM) , 1 ul each of 20 μM solutions of primer (see infra) , and 1.25 units of Taq polymerase. Water was added to a final volume of 50 uls. The primers used for MAGE-3 were: 5'-TGGAGGACCAGAGGCCCCC-3' (SEQ ID NO: 27) 5'-GGACGATTATCAGGAGGCCTGC-3' (SEQ ID NO: 28) These correspond to a sense sequence in exon 2 of the gene (SEQ ID NO: 27) , and an antisense sequence in exon 3 (SEQ ID NO: 28) . PCR was performed for 30 cycles (one minute at 94°C, four minutes at 72°C) . PCR products were size fractionated on a 1% agarose gel, and then analyzed. The results are presented in the table which follows. These data confirm some results obtained previously, but also show the expression of MAGE-3 in head and neck squamous cell carcinomas, a result not suggested by previous work. Table 8. Expression of gene MΛGE-3 by liimoral, normal and fetal tissues. TUMORS NORMAL TISSUKS IIISTOLOGFCAL TYPE 1 IISTOLOGICAL TYPE AGE-3 expression" 1 ADULT TISSUES Drain Melanomas Colon Stomach Mead and neck squamous cell carcinomas Liver Ovary Lung carcinomas Skin NSCLC t Lung CO cz SCLC Kidney CO Breast Colorectal carcinomas Testis ++ Mammary carcinomas FETAL TISSUES Bladder tumors Brain Liver Sarcomas Spleen Prostatic carcinomas Renal carcinomas Leukemias Ly phomas ♦ Expression of gene MAGE-3 was tested by RT-PCR amplification on total RNA, with the primers described in methods. These primers distinguish MAGE-3 from the 1 1 other MAGE genes that have been identified. φ NSCLC are non-smattcell lung carcinomas, SCLC are small cell lung carcinomas. Example 48 Bladder tumor specimens were collected at surgery. They were divided into two portions, one of which was used for routine histopathological evaluation. The other portion was frozen in liquid nitrogen immediately after transurethral resection, or radical cystectomy. These frozen samples were stored at -80°C until used for RNA extraction. Normal bladder tissue was obtained by biopsies of cadavers from donors in an organ transplant program. Total RNA was extracted from the samples by the classic guanidine-isothiocyanate/cesium chloride method of Davis et al, Basic Methods in Molecular Biology, pp. 130- 135, Elsevier, New York (1986) . Synthesis of cDNA was then carried out by extension with oligo(dT) using 2 ug of RNA in a 20 ul reaction volume following DeSmet et al., Immunogenetics 39: 121-129 (1994), incorporated by reference herein. Following incubation at 42°C for one hour, the cDNA reaction mixture was diluted to 100 ul with water. Separate polymerase chain reaction amplification were then carried out to determine whether any of MAGE-1, 2, 3 or 4 cDNA were present. The amplifications were carried out using oligonucleotide primers located in different exons of the MAGE genes. PCR amplification was also carried out using primers for HLA-Al. The primers used were the following: 5'-TGGAGGACCAGAGGCCCCC-3 (sense, exon 2) (SEQ ID NO: 27) and 5'-GGACGATTATCAGGAGGCCTGC-3' (antisense, exon 3) (SEQ ID NO: 28) for MAGE-3 5'-CGGCCGAAGGAACCTGACCCAG-3' (sense, exon 1) (SEQ ID NO: 47) and 5'GCTGGAACCCTCACTGGGTTGCC-3' (anti-sense, exon 3) (SEQ ID NO: 48) for MAGE-1 5'-AAGTAGGACCCGAGGCACTG-3' (sense, exon 2) (SEQ ID NO: 49) and 5'-GAAGAGGAAGAAGCGGTCTG-3' (anti-sense, exon 3) (SEQ ID NO: 50) for MAGE-2 5'-GAGCAGACAGGCCAACCG-3' (sense, exon 2) (SEQ ID NO: 29) and 5'-AAGGACTCTGCGTCAGGC-3' (anti-sense, exon 3) (SEQ ID NO: 30) for MAGE-4 5'-GGGACCAGGAGACACGGAATA-3' (sense, exon 2) (SEQ ID NO: 51) and 5'-AGCCCGTCCACGCACCG-3' (anti-sense, exon 3) (SEQ ID NO: 52) for HLA-Al SEQ ID NOS: 27 and 28 are described by Weynants et al., Int. J. Cancer 56: 826-829 (1994). SEQ ID NOS: 47 and 48 are described in Brasseur et al., Int. J. Cancer 52: 839- 841 (1992) . SEQ ID NOS: 49 and 50 are disclosed in DeSmet et al., Immunogenetics 39: 121-129 (1994). SEQ ID NOS: 29 and 30 are disclosed in copending application Serial No. 08/299,849 filed September 1, 1994 to DePlaen et al., and incorporated by reference. SEQ ID NOS: 51 and 52 are found in Gaugler et al., J. Exp. Med. 179: 921-930 (1994), as well as the above-identified parent application. All of these references are incorporated by reference. The amplification protocol was as follows. Each PCR reaction used 5 ul of cDNA, supplemented with 5 ul of lOx PCR buffer, 1 ul each of 10 mM dNTP, 0.5 ul each of 80 uM solutions of primers, 1.25 units of Taq DNA polymerase, and water to achieve a total volume of 50 ul. The mixtures were heated to 94°C for 5 minutes, followed by amplification in a thermal cycler, for 30 cycles. For MAGE-1, 1 cycle was one minute at 94°C followed by three minutes at 72°C. For MAGE-2, one cycle was 94°C for one minute, followed by two minutes at 67°C and two minutes at 72°C. For MAGE-3, one cycle was one minute at 94°C; followed by four minutes at 72°C. For MAGE-4, one cycle was one minute at 94°C, two minutes at 68°C, and two minutes at 72°C. The cycle for HLA-Al was the same as that for MAGE-4. A 10 ul sample of each reaction was run on a 1% agarose gel, and then visualized by ethidium bromide fluorescence. In order to provide a control for RNA integrity, a 20 cycle PCR assay, using primers specific for β actin, was carried out in each case, following Weynants et al. , supra. The protocols described were developed with certain goals in mind. Primers were selected so as to be in different exons, thus preventing false positives due to DNA contamination of the RNA preparations. Under the conditions used, DNA generates either no PCR product, or longer products which are readily distinguishable from amplified cDNA. This is shown by figure 19. In figure 19, a bladder tumor sample from a patient, referred to as "HM15" is shown in each "R" lane. Lanes marked "D" show products obtained from amplification of the patients' genomic DNA. The PCR products were run on a 2.5% low melting agarose gel, but the assays were identical to the protocol of this example in all other ways. Size markers are on the left hand side. There was no band in the MAGE-1 reaction, because of the large intron between the two primers. Table 10, which follows, shows the results obtained for a number of tumors (nomenclature is explained below) . Of 57 samples of primary transitional cell carcinoma, 21% expressed MAGE-1, 30% expressed MAGE-2, 35% expressed MAGE- 3, and 33% expressed MAGE-4. Ta tumors and low grade Tl tumors expressed none of these, or expressed only a single gene, at low levels. Higher stage tumors, in contrast, frequently expressed high levels of several genes. It was also found that the fraction of invasive tumors which expressed MAGE genes was 2-5 times higher than the fraction observed with superficial tumors, as is depicted in figure 2 (this figure is based upon data from Table 10) . Tumors expressing at least one of the four MAGE genes accounted for 61% of the 28 invasive tumors studied. Among the 29 superficial tumors, the proportion was only 28%. Results paralleled other results reported previously for melanoma, in that all but one of the tumors expressing MAGE-1 also expressed MAGE-3. None of the six biopsies of normal bladder examined expressed any of the MAGE genes discussed herein. In some instances, several tumor samples were obtained from the same patient. The analysis of these patients is set out in Table 9. Patient HM61 had a primary tumor and an invaded lymph node. They displayed a very similar pattern of expression of MAGE-1, 2, and 3, with MAGE-1 predominating. Normal mucosa adjacent to the tumor was completely negative for MAGE-2 and MAGE-3, with a very low level of MAGE-1 expression, which was probably due to the presence of a few tumor cells. In patient "HM25", the initial tumor, and an early recurrence, both expressed MAGE-1, 2, 3 and 4. A recurrence which occurred two years after the first displayed a very different pattern, expressing only MAGE-2 and MAGE-3. A similar discordance between primary tumor and recurrence was observed with patient "HM20". Patients HM30 and LB526 showed differences in the pattern of MAGE-expression in different samples of the same primary tumor. In the tables which follow, "Ta" stands for a superficial lesion, limited to bladder mucosa (also known as "stage Ta") . "Stage Tl", or » τi" is used for superficial lesions limited to subepithelial connective tissue. "Stages T2-T4", or "T2-T4" refer to tumors which have invaded bladder muscle. The nomenclature "Gl", "G2" and "G3" refers to the degree of differentiation, or histopathological grade. "Gl" superficial tumor is well differentiated, while a "G3" tumor is poorly differentiated. See Mostofi et al., "Histological Typing of Urinary Bladder Tumors. WHO International Histological Classification of Tumors" (1973) . TABLE 9 - EXPRESSION OF GENES MAGE-1, 2, 3 AND 4 IN MULTIPLE SAMPLES FROM BLADDER CARCINOMA PATIENTS Tumor stage Patients Samples HM 61 Primary tumor Metastatic iliac lymph node Mucosa adjacent to the tumor HM 25 Primary tumor Tumor recurrence after 1 month Tumor recurrence after 2 years HM 20 Primary tumor σ» Tumor recurrence after 2 months HM 30 Primary tumor, 1st sample Primary tumor, 2nd sample LB 526 Primary tumor, radical cystectomy Primary tumor, 9-day pre-operative bi 62 Table 10 --XPRESSION OF GENES MACE-1.2. 3 AND 4 IN BLADDER TRANSITIONAL-CELL CARCINOMA SAMPLES Tumor Stage and Grade * Patients MAGE-1 MAGE-2 MAGE-3 MAGE-4^ Su eriic-aj tumors in-29] ♦♦♦ ♦*♦ *** ♦ + * ♦ The foregoing examples show that expression of MAGE tumor rejection antigen precursors is correlated to various cancers. One aspect of the invention, then, is a method for determining these cancers by assaying a sample for expression of at least one MAGE tumor rejection antigen precursor. As MAGE genes are nearly without exception expressed only by tumor cells, there can be no question but that expression of a MAGE gene or genes is indicative of cancer. The fact that the cancer is a particular type, such as lung adenocarcinoma, is easily ascertainable, as adenocarcinoma cells have distinct morphologies which are identifiable by the skilled artisan. Similarly, the fact that the tumor of interest is a lung adenocarcinoma as compared to a tumor from a different body part is self evident; one does not find lung adenocarcinoma in, e.g., large intestine tissue. Analogous statements can be made for bladder and other cancers. The assay for the MAGE genes can take many forms. Most preferably, the assay is done via determining gene expression, such as by determining mRNA transcription products. For example, amplification protocols, including but not being limited to polymerase chain reaction (PCR) , and ligase chain reaction (LCR) , are preferred. The assay can also be carried out using nucleic acid molecule probes, which are labelled or unlabelled, and which specifically hybridize to sequences characteristic of the MAGE gene of interest. Labelling nucleotide probes is well known to the art, labels including radioactive, fluorescent, chromophoric, magnetic, and other identifiable materials. Antibodies, haptens such as biotin, (strept)avidin, digoxin, digoxigenin, and so forth, can all be used. Non- labelled probes can also be used. In such a case, the probes will form a double stranded molecule with their target. Any remaining single stranded material can be enzymatically digested, and when something remains, it is a sign of MAGE expression. For the case of polymerase chain reaction or other methodologies where a primer or primers are required, the molecules represented by SEQ ID NO: 47 and SEQ ID NO: 48 are especially preferred for MAGE- 1, SEQ ID NO: 49 and 50 for MAGE-2, SEQ ID NOS: 27 and 28 for MAGE-3 and SEQ ID NOS: 29 and 30 for MAGE-4. Similarly, these molecules are preferred as probes. Quantitation of MAGE expression is shown herein as well. This is an important feature of the invention because in a given tumor sample (as compared to tumor cell lines) there will always be an undetermined proportion of normal cells. One may also assay for the expression product of the MAGE gene, e.g., the tumor rejection antigen precursor protein, via assays such as immunoassays. See, e.g., U.S. Patent Application Serial No. 08/190,411 filed February 1, 1994, and Chen, et al., Proc. Natl. Acad. Sci. USA 91(3): 1004-1008 (1994), both of which are incorporated by reference, teaching MAGE-1 specific mAbs. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, it being recognized that various modifications are possible within the scope of the invention. (1) GENERAL INFORMATION: (i) APPLICANTS: De Plaen, Etienne; Boon-Falleur, Thierry; Lethe, Bernard; Szikora, Jean-Pierre; De Smet, Charles; Chomez, Patrick; Weynants, P.; Brasseur, Francis; Marchand, M. ; Gaugler, Beatrice; Van den Eynde, Benoit; van der Bruggen, Pierre; Patard, Jean-Jacques (ii) TITLE OF INVENTION: Method For Determining A Cancerous Condition by Assaying For Expression Of One Or More Mage Tumor Rejection Antigen Precursors (iii) NUMBER OF SEQUENCES: 56 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Felfe & Lynch (B) STREET: 805 Third Avenue (C) CITY: New York City (D) STATE: New York (F) ZIP: 10022 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage (B) COMPUTER: IBM (C) OPERATING SYSTEM: PC-DOS (D) SOFTWARE: WordPerfect (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Hanson, Norman D. (B) REGISTRATION NUMBER: 30,946 (C) REFERENCE/DOCKET NUMBER: LUD 5356-PCT (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (212) 688-9200 (B) TELEFAX: (212) 838-3884 (2) INFORMATION FOR SEQUENCE ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 462 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: ACCACAGGAG AATGAAAAGA ACCCGGGACT CCCAAAGACG CTAGATGTGT 50 GAAGATCCTG ATCACTCATT GGGTGTCTGA GTTCTGCGAT ATTCATCCCT 100 CAGCCAATGA GCTTACTGTT CTCGTGGGGG GTTTGTGAGC CTTGGGTAGG 150 AAGTTTTGCA AGTTCCGCCT ACAGCTCTAG CTTGTGAATT TGTACCCTTT 200 CACGTAAAAA AGTAGTCCAG AGTTTACTAC ACCCTCCCTC CCCCCTCCCA 250 CCTCGTGCTG TGCTGAGTTT AGAAGTCTTC CTTATAGAAG TCTTCCGTAT 300 AGAACTCTTC CGGAGGAAGG AGGGAGGACC CCCCCCCTTT GCTCTCCCAG 350 CATGCATTGT GTCAACGCCA TTGCACTGAG CTGGTCGAAG AAGTAAGCCG 400 CTAGCTTGCG ACTCTACTCT TATCTTAACT TAGCTCGGCT TCCTGCTGGT 450 ACCCTTTGTG CC 462 (2) INFORMATION FOR SEQUENCE ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 675 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: ATG TCT GAT AAC AAG AAA CCA GAC AAA GCC CAC AGT GGC TCA GGT GGT 48 Met Ser Asp Asn Lys Lys Pro Asp Lys Ala His Ser Gly Ser Gly Gly 5 10 15 GAC GGT GAT GGG AAT AGG TGC AAT TTA TTG CAC CGG TAC TCC CTG GAA 96 Asp Gly Asp Gly Asn Arg Cys Asn Leu Leu His Ar T r Ser Leu Glu 20 25 GAA ATT CTG CCT TAT CTA GGG TGG CTG GTC TTC 144 Glu lie Leu Pro Tyr Leu Gly Trp Leu Val Phe 35 40 AGT TTT CTG GCG CTC CAG ATG TTC ATA GAC GCC 192 Ser Phe Leu Ala Leu Gin Met Phe lie Asp Ala 50 55 TAT GAA AGG GAT GTG GCC TGG ATA GCC AGG CAA 240 Tyr Glu Arg Asp Val Ala Trp lie Ala Arg Gin Ser Lys Arg Met Ser 65 70 75 80 TCT GTC GAT GAG GAT GAA GAC GAT GAG GAT GAT GAG GAT GAC TAC TAC 288 Ser Val Asp Glu Asp Glu Asp Asp Glu Asp Asp Glu Asp Asp Tyr Tyr 85 90 95 GAC GAC GAG GAC GAC GAC GAC GAT GCC TTC TAT GAT GAT GAG GAT GAT 336 Asp Asp Glu Asp Asp Asp Asp Asp Ala Phe Tyr Asp Asp Glu Asp Asp 100 105 110 GAG GAA GAA GAA TTG GAG AAC CTG ATG GAT GAT GAA TCA GAA GAT GAG 384 Glu Glu Glu Glu Leu Glu Asn Leu Met Asp Asp Glu Ser Glu Asp Glu 115 120 125 GCC GAA GAA GAG ATG AGC GTG GAA ATG GGT GCC GGA GCT GAG GAA ATG 432 Ala Glu Glu Glu Met Ser Val Glu Met Gly Ala Gly Ala Glu Glu Met 130 135 140 GGT GCT GGC GCT AAC TGT GCC TGT GTT CCT GGC CAT CAT TTA AGG AAG 480 Gly Ala Gly Ala Asn Cys Ala Cys Val Pro Gly His His Leu Arg Lys 145 150 155 160 AAT GAA GTG AAG TGT AGG ATG ATT TAT TTC TTC CAC GAC CCT AAT TTC 528 Asn Glu Val Lys Cys Arg Met lie Tyr Phe Phe His Asp Pro Asn Phe 165 170 175 CTG GTG TCT ATA CCA GTG AAC CCT AAG GAA CAA ATG GAG TGT AGG TGT 576 Leu Val Ser lie Pro Val Asn Pro Lys Glu Gin Met Glu Cys Arg Cys 180 185 190 GAA AAT GCT GAT GAA GAG GTT GCA ATG GAA GAG GAA GAA GAA GAA GAG 624 Glu Asn Ala Asp Glu Glu Val Ala Met Glu Glu Glu Glu Glu Glu Glu 195 200 210 GAG GAG GAG GAG GAA GAG GAA ATG GGA AAC CCG GAT GGC TTC TCA CCT 672 Glu Glu Glu Glu Glu Glu Glu Met Gly Asn Pro Asp Gly Phe Ser Pro 220 225 230 235 TAG 675 (2) INFORMATION FOR SEQUENCE ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 228 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3s GCATGCAGTT GCAAAGCCCA GAAGAAAGAA ATGGACAGCG GAAGAAGTGG TTGTTTTTTT 60 TTCCCCTTCA TTAATTTTCT AGTTTTTAGT AATCCAGAAA ATTTGATTTT GTTCTAAAGT 120 TCATTATGCA AAGATGTCAC CAACAGACTT CTGACTGCAT GGTGAACTTT CATATGATAC 180 ATAGGATTAC ACTTGTACCT GTTAAAAATA AAAGTTTGAC TTGCATAC 228 (2) INFORMATION FOR SEQUENCE ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1365 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: ACCACAGGAG AATGAAAAGA ACCCGGGACT CCCAAAGACG GAAGATCCΪG ATCACTCATT GGGTGTCTGA GTTCTGCGAT CAGCCAATGA GCTTACTGTT CTCGTGGGGG GTTTGTGAGC AAGTTTTGCA AGTTCCGCCT ACAGCTCTAG CTTGTGAATT CACGTAAAAA AGTAGTCCAG AGTTTACTAC ACCCTCCCTC CCTCGTGCTG TGCTGAGTTT AGAAGTCTTC CTTATAGAAG AGAACTCTTC CGGAGGAAGG AGGGAGGACC CCCCCCCTTT CATGCATTGT GTCAACGCCA TTGCACTGAG CTGGTCGAAG CTAGCTTGCG ACTCTACTCT TATCTTAACT TAGCTCGGCT ACCCTTTGTG CC ATG TCT GAT AAC AAG AAA CCA GAC AAA GCC CAC GGT GGT GAC GGT GAT GGG AAT AGG TGC AAT TTA TAC TCC CTG GAA GAA ATT CTG CCT TAT CTA GGG TTC GCT GTT GTC ACA ACA AGT TTT CTG GCG CTC ATA GAC GCC CTT TAT GAG GAG CAG TAT GAA AGG TGG ATA GCC AGG CAA AGC AAG CGC ATG TCC TCT GAT GAA GAC GAT GAG GAT GAT GAG GAT GAC TAC GAG GAC GAC GAC GAC GAT GCC TTC TAT GAT GAT GAG GAA GAA GAA TTG GAG AAC CTG ATG GAT GAT GAT GAG GCC GAA GAA GAG ATG AGC GTG GAA ATG GCT GAG GAA ATG GGT GCT GGC GCT AAC TGT GCC GGC CAT CAT TTA AGG AAG AAT GAA GTG AAG TGT TAT TTC TTC CAC GAC CCT AAT TTC CTG GTG TCT AAC CCT AAG GAA CAA ATG GAG TGT AGG TGT GAA GAA GAG GTT GCA ATG GAA GAG GAA GAA GAA GAA GAG GAG GAA GAG GAA ATG GGA AAC CCG GAT GGC TAG GCATGCAGTT GCAAAGCCCA GAAGAAAGAA ATGGACAGCG TTGTTTTTTT TTCCCCTTCA TTAATTTTCT AGTTTTTAGT ATTTGATTTT GTTCTAAAGT TCATTATGCA AAGATGTCAC CTGACTGCAT GGTGAACTTT CATATGATAC ATAGGATTAC GTTAAAAATA AAAGTTTGAC TTGCATAC (2) INFORMATION FOR SEQUENCE ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4698 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: ACCACAGGAG AATGAAAAGA ACCCGGGACT CCCAAAGACG GAAGATCCTG ATCACTCATT GGGTGTCTGA GTTCTGCGAT CAGCCAATGA GCTTACTGTT CTCGTGGGGG GTTTGTGAGC AAGTTTTGCA AGTTCCGCCT ACAGCTCTAG CTTGTGAATT CACGTAAAAA AGTAGTCCAG AGTTTACTAC ACCCTCCCTC CCTCGTGCTG TGCTGAGTTT AGAAGTCTTC CTTATAGAAG AGAACTCTTC CGGAGGAAGG AGGGAGGACC CCCCCCCTTT CATGCATTGT GTCAACGCCA TTGCACTGAG CTGGTCGAAG CTAGCTTGCG ACTCTACTCT TATCTTAACT TAGCTCGGCT ACCCTTTGTG CC ATG TCT GAT AAC AAG AAA CCA GAC AAA GCC CAC GGT GGT GAC GGT GAT GGG AAT AGG TGC AAT TTA TAC TCC CTG GAA GAA ATT CTG CCT TAT CTA GGG TTC GCT GTT GTC ACA ACA AGT TTT CTG GCG CTC ATA GAC GCC CTT TAT GAG GAG CAG TAT GAA AGG TGG ATA GCC AGG CAA AGC AAG CGC ATG TCC TCT GAT GAA GAC GAT GAG GAT GAT GAG GAT GAC TAC GAG GAC GAC GAC GAC GAT GCC TTC TAT GAT GAT GAG GAA GAA GAA TTG GAG AAC CTG ATG GAT GAT GAT GAG GCC GAA GAA GAG ATG AGC GTG GAA ATG GCT GAG GAA ATG GGT GCT GGC GCT AAC TGT GCC GTGAGTAACC CGTGGTCTTT ACTCTAGATT CAGGTGGGGT CTCTTGCCCA CATCTGTAGT AAAGACCACA TTTTGGTTGG TGGAGCCATT CCTGGCTCTC CTGTCCACGC CTATCCCCGC CCCCACTCCT TGCTCCGCTC TCTTTCCTTT TCCCACCTTG TTCAGTCCAT CCTGCTCTGC TCCCTTTCCC CTTTGCTCTC TCCCCCTCGG CTCAACTTTT CGTGCCTTCT GCTCTCTGAT TTCAGGCTTC CCCATTTGCT CCTCTCCCGA AACCCTCCCC CCTTTTCGCG CCTTTTCTTT CCTGCTCCCC TCCCCCTCCC TCACCAGCTT TGCTCTCCCT GCTCCCCTCC CCCTTTTGCA TCCTGCTCCC CTCCCCCTCC CCTCCCTGTT TACCCTTCAC CTACCTGCTT CCCTCCCCCT TGCTGCTCCC TCCCTATTTG TGCTCCTCCC TCCCCCTCCC CCTCCCTCCC TATTTGCATT CCTCCCTCCC CCTCCCCAGG CCTTTTTTTT TTTTTTTTTT TTGGTTTTTC GAGACAGGGT TTCTCTTTGT ATCCCTGGCT TCACTCTGTA GACCAGGCTG GCCTCAAACT CAGAAATCTG CCTCCCAAAT GCTGGGATTA AAGGCTTGCA CCAGGACTGC GCCTTTCTTT TTTCTCCTCT CTGGTCTCCC TAATCCCTTT AACTCCCCTT TTGGCACCTT TCCTTTACAG GACCCCCTCC TTCCCTTCCG GCACCCTTCC TAGCCCTGCT CTGTTCCCTC CCTCCCCCTC TTTGCTCGAC TTTTAGCAGC CTTACCTCTC GCCCCGTTCC CCTTTTTTGT GCCTTTCCTC CTGGCTCCCC AGCTCACCTT TTTGTTTGTT TGGTTGTTTG GTTGTTTGGT TTTTTTTTTT GCACCTTGTT TTCCAAGATC CCCCTCCCCC CCTCTGTGTG CCTTTCCTGT TCCCTCCCCC TCGCTGGCTC TCTGCCTTTC CTGTCCCTGC TCCCTTCTCT GCTAACCTTT CTTTTCTAGA CTCCCCCCTC CAGGCTTGCT GTTTGCTTCT CCTGACCCTG CTCCCCTTCC CCTCCCAGCT CCCCCCTCTT CCTTTCTCCA GCCTGTCACC CCTCCTTCTC TCCTCTCTGT TCCTGCTTCC TTTACCCCTT CCCTCTCCCT ACTCTCCTCC GACTTCCTCT CCAGCCGCCC AGTTCCCTGC AGTCCTGGAG CTCTCTGTCC ATCACTTCCC CCTAGTTTCA CTTCCCTTTC ATGTGTCTCT CTTCCTATCT ATCCCTTCCT TTCTGTCCCC CCATCACCTC TCTCCTCCCT TCCCTTTCCT CTCTCTTCCA CCTGCTTCTT TACCCTGCCT CTCCCATTGC CCTCTTACCT TCCATGTCCC CTCTCAATTC CCTGTCCCAT TGTGCTCCCT ATTTCCCTCT TTCTCCCTTA GCCTCTTCTT CCTCTTCTCT TTCCCTTTGC TTCTCCCTCC TCCTTTCCCC TTCCCCTATG TACTTGATCT TCTCTCCTCT CCACATACCC TTTTTCCTTT CTTTGTCCCC AGACCCTACA GTATCCTGTG CACAGGAAGT ATCAACAACA AGGAGGCAAG AAACAGAGCA AAATCCCAAA AAGGCTGGAT GAAAATAAGG CCAGGTTCTG AGGACAGCTG AAGTGGCTCC TATAACCCTA AGTACCAAGG GAGAAAGTGA CTTGATCCTT GCTGCTTCTT TTACATATGT TGGCACATCT CAGGCCATGC TCCATGCTTG GCGCTTGCTC AGCGTGGTTA GAATCTGAAA ACTAGGGGCC AGTGGTTTGT TTTGGGGACA TAGTGATATT TCCCCCTAAA AATTATAACA AACAGATTCA TCCTTCTACA GGTGAGAAGT GGAAAAATTG TCACTATGAA GGCTAAAGAT ACTTGGAACC ATAGAAGCGT TGTTAAAATA TTGCTAAAAT ATTCTTTCTC ACATATTCAT ATTCTCCAG GT GTT CCT GGC CAT CAT TTA AGG AAG AAT GAA AGG ATG ATT TAT TTC TTC CAC GAC CCT AAT TTC ATA CCA GTG AAC CCT AAG GAA CAA ATG GAG TGT AAT GCT GAT GAA GAG GTT GCA ATG GAA GAG GAA GAG GAG GAG GAG GAG GAA GAG GAA ATG GGA AAC TTC TCA CCT TAG GCATGCAGGT ACTGGCTTCA CTAACCAACC ATTCCTAACA GCTAAGAGCA TCTTTTTAAA AAATATTATT GGTAAACTAA TCTTTTTACA TTAATAAGTA TTAAATTAAT CCAGTATACA CCCTAAGTTA AACAGAAGTC AATGATGTCT AGATGCCTGT GTAGTGAGAC TACTTACTAC AGATGAGAAG TTGTTAGACT GACCAGTAAA AGATCATGCA GTGAAATGTG GCCATGGAAA TTCTTATAGT ACCTTTGAGA CAGCTGATAA CAGCTGACAA TTCAAGAAAG ATCACACGCC ATGGTTCACA TGCAAATTAT TTCTGATTTT TTTCATTTCT AGACCTGTGG TTTTAAAGAG CTTAAAATTT CCTTCATCTT TAATTTTCCT TAACTTTAGT TAGAATTCAA TTCAAATTCT TAATTCAATC TTAATTTTTA AATGTTTTTT AAAAAAAATG CAAATCTCAT TTTTAAGAGA GTAACTGGGG GGCTTAGGGA ATCTGTAGGG TTGCGGTATA GTTCTGGTCT CTGAGAAGCA GTCAGAGAGA ATGGAAAACC CAGTAGGTTA GTGAGGTTGA TATGATCAGA TTATGGACAC ATAAATACTC TAACAGCTAA GGATCTCTGA GGGAAACACA ATTTTAGTTT CTCCTTGAGA AACAATGACA AGACATAAAA AGTCAGGAGT GTATTCTAAT AAGTGTTGCT TATCTCTTAT AGTTGCAAAG CCCAGAAGAA AGAAATGGAC AGCGGAAGAA TTTTTTCCCC TTCATTAATT TTCTAGTTTT TAGTAATCCA TTTTGTTCTA AAGTTCATTA TGCAAAGATG TCACCAACAG GCATGGTGAA CTTTCATATG ATACATAGGA TTACACTTGT AATAAAAGTT TGACTTGCAT AC (2) INFORMATION FOR SEQUENCE ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: Leu Pro Tyr Leu Gly Trp Leu Val Phe 5 (2) INFORMATION FOR SEQUENCE ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2418 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: GGATCCAGGC CCTGCCAGGA AAAATAT AG GGCCCTGCGT GAGAACAGAG 50 GGGGTCATCC ACTGCATGAG AGTGGGGATG TCACAGAGTC CAGCCCACCC 100 (2) INFORMATION FOR SEQUENCE ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5724 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-1 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: TGCCACAGGA CACATAGGAC TCCACAGAGT CTGGCCTCAC CTCCCTACTG 3650 TCAGTCCTGT AGAATCGACC TCTGCTGGCC GGCTGTACCC TGAGTACCCT 3700 CTCACTTCCT CCTTCAGGTT TTCAGGGGAC AGGCCAACCC AGAGGACAGG 3750 ATTCCCTGGA GGCCACAGAG GAGCACCAAG GAGAAGATCT GTAAGTAGGC 3800 CTTTGTTAGA GTCTCCAAGG TTCAGTTCTC AGCTGAGGCC TCTCACACAC 3850 TCCCTCTCTC CCCAGGCCTG TGGGTCTTCA TTGCCCAGCT CCTGCCCACA 3900 CTCCTGCCTG CTGCCCTGAC GAGAGTCATC 3930 ATG TCT CTT GAG CAG AGG AGT CTG CAC TGC AAG CCT GAG GAA 3972 GCC CTT GAG GCC CAA CAA GAG GCC CTG GGC CTG GTG TGT GTG 4014 CAG GCT GCC ACC TCC TCC TCC TCT CCT CTG GTC CTG GGC ACC 4056 CTG GAG GAG GTG CCC ACT GCT GGG TCA ACA GAT CCT CCC CAG 4098 AGT CCT CAG GGA GCC TCC GCC TTT CCC ACT ACC ATC AAC TTC 4140 ACT CGA CAG AGG CAA CCC AGT GAG GGT TCC AGC AGC CGT GAA 4182 GAG GAG GGG CCA AGC ACC TCT TGT ATC CTG GAG TCC TTG TTC 4224 CGA GCA GTA ATC ACT AAG AAG GTG GCT GAT TTG GTT GGT TTT 4266 CTG CTC CTC AAA TAT CGA GCC AGG GAG CCA GTC ACA AAG GCA 4308 GAA ATG CTG GAG AGT GTC ATC AAA AAT TAC AAG CAC TGT TTT 4350 CCT GAG ATC TTC GGC AAA GCC TCT GAG TCC TTG CAG CTG GTC 4392 TTT GGC ATT GAC GTG AAG GAA GCA GAC CCC ACC GGC CAC TCC 4434 TAT GTC CTT GTC ACC TGC CTA GGT CTC TCC TAT GAT GGC CTG 4476 CTG GGT GAT AAT CAG ATC ATG CCC AAG ACA GGC TTC CTG ATA 4518 ATT GTC CTG GTC ATG ATT GCA ATG GAG GGC GGC CAT GCT CCT 4560 GAG GAG GAA ATC TGG GAG GAG CTG AGT GTG ATG GAG GTG TAT 4602 GAT GGG AGG GAG CAC AGT GCC TAT GGG GAG CCC AGG AAG CTG 4644 CTC ACC CAA GAT TTG GTG CAG GAA AAG TAC CTG GAG TAC GGC 4686 AGG TGC CGG ACA GTG ATC CCG CAC GCT ATG AGT TCC TGT GGG 4728 GTC CAA GGG CCC TCG CTG AAA CCA GCT ATG TGA 4761 AAGTCCTTGA GTATGTGATC AAGGTCAGTG CAAGAGTTC 4800 GCTTTTTCTT CCCATCCCTG CGTGAAGCAG CTTTGAGAGA GGAGGAAGAG 4850 GGAGTCTGAG CATGAGTTGC AGCCAAGGCC AGTGGGAGGG GGACTGGGCC 4900 AGTGCACCTT CCAGGGCCGC GTCCAGCAGC TTCCCCTGCC TCGTGTGACA 4950 TGAGGCCCAT TCTTCACTCT GAAGAGAGCG GTCAGTGTTC TCAGTAGTAG 5000 GTTTCTGTTC TATTGGGTGA CTTGGAGATT TATCTTTGTT CTCTTTTGGA 5050 ATTGTTCAAA TGTTTTTTTT TAAGGGATGG TTGAATGAAC TTCAGCATCC 5100 AAGTTTATGA ATGACAGCAG TCACACAGTT CTGTGTATAT AGTTTAAGGG 5150 TAAGAGTCTT GTGTTTTATT CAGATTGGGA ATCCATTCT ATTTTGTGAA 5200 TTGGGATAAT AACAGCAGTG GAATAAGTAC TTAGAAATGT GAAAAATGAG 5250 CAGTAAAATA GATGAGATAA AGAACTAAAG AAATTAAGAG ATAGTCAATT 5300 CTTGCCTTAT ACCTCAGTCT ATTCTGTAAA ATTTTTAAAG ATATATGCAT 5350 ACCTGGATTT CCTTGGCTTC TTTGAGAATG TAAGAGAAAT TAAATCTGAA 5400 TAAAGAATTC TTCCTGTTCA CTGGCTCTTT TCTTCTCCAT GCACTGAGCA 5450 TCTGCTTTTT GGAAGGCCCT GGGTTAGTAG TGGAGATGCT AAGGTAAGCC 5500 AGACTCATAC CCACCCATAG GGTCGTAGAG TCTAGGAGCT GCAGTCACGT 5550 AATCGAGGTG GCAAGATGTC CTCTAAAGAT GTAGGGAAAA GTGAGAGAGG 5600 GGTGAGGGTG TGGGGCTCCG GGTGAGAGTG GTGGAGTGTC AATGCCCTGA 5650 GCTGGGGCAT TTTGGGCTTT GGGAAACTGC AGTTCCTTCT GGGGGAGCTG 5700 ATTGTAATGA TCTTGGGTGG ATCC 5724 (2) INFORMATION FOR SEQUENCE ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4157 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-2 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: GCTGCCTCTG CTGCCGGGCC TGGACCACCC TGCAGGGGAA GCTCAGTCGC CACCACCTCA CCCCGCCACC CCCCGCCGCT GGAACTCTGG CGTAAGAGCT TTGTGTGACC AGGGCAGGGC TGCTCAGGGC CCAGACTCAG CCAGGAATCA AGGTCAGGAC GACTGAGGGC AACCCACCCC CTACCCTCAC TACCAATCCC ACCAACCCCA CCCCCATCCC TCAAACACCA ACCCCACCCC TCCCATCTCC TCCCCCACCA CCATCCTGGC AGAATCCGGC CAATCAACCC ACGGAAGCTC CGGGAATGGC GGCCAAGCAC ACGTTCACAT GTACGGCTAA GGGAGGGAAG GGGTTGGGTC GGCCTTTGGG ATGCAGAGGA AGGGCCCAGG CCTCCTGGAA TCCTTAGGGG ACCCAGCATG CCAGGACAGG GGGCCCACTG TCAAACTGAG CCACCTTTTC ATTCAGCCGA GGGAATCCTA CCCACTTCAG GGGGTTGGGG CCCAGCCTGC GAGGAGTCAA AAGAGGGAGG ACTGAGGGGA CCTTGGAGTC CAGATCAGTG GCTGGGGGAT CCTGGGCACA GTGGCCGAAT GTGCCCCGTG CTTCAGGGTG ACAGAGAGTT GAGGGCTGTG GTCTGAGGGC GGTCAGCAGA GGGAGGAATC CCAGGATCTG CCGGACCCAA CTTCATGAGG ACTCCCCATA CCCCCGGCCC AGAAAGAAGG AGTCTGGAAG TAAATTGTTC TTAGCTCTGG GGGAACCTGA CCCTAAGTGA CAATCTCATT TGTACCACAG GCAGGAGGTT CAGGGAGATA AGGTGTTGGT GTAAAGAGGA GCTGTCTGCT GGTTCCCCCT TGAGAAAGGG CAGTCCCTGG CAGGAGTAAA CCACAGGAGG CCATCATAAC GTTCACCCTA GAACCAAAGG GGACAACGCA CGTGGGGTAA CAGGATGTGG CCCCTCCTCA CAGATCTCAG GGAGTTGATG ACCTTGTTTT CAGAAGGTGA ACAGGGGCCC CTCTGGTCGA CAGATGCAGT GGTTCTAGGA ATCCAGGTGG AGAGCCTGAG GTAGGATTGA GGGTACCCCT GCAGCAAGGG GGCCCCATAG AAATCTGCCC TGCCCCTGCG AGACCCTGGG CAGGGCTGTC AGCTGAAGTC CCTCCATTAT TGATGTCAGG GAAGGGGAGG CCTTGGTCTG AAGGGGCTGG GTAGAGGGAG GGTCTCAGGC CCTGCCAGGA GTGGACGTGA GACTCGTCAC CCAGGACACC TGGACTCCAA TGAATTTGAC GTCCTTCGCG GAGGACCTGG TCACGTATGG CCAGATGTGG TCTCCTTCTG TACCATATCA GGGATGTGAG TTCTTGACAT CAAGCCAGCA AAAGGGTGGG ATTAGGCCCT ACAAGGAGAA CCTGAGTGAG CACAGAGGGG ACCCTCCACC CAAGTAGAGT CGGAGTCTGG CCAACCCTGC TGAGACTTCT GGGAATCCGT GCAGTCTGCA CACTGAAGGC CCGTGCATTC CTCTCCCAGG TCCAGGAACC AGGCAGTGAG GCCTTGGTCT GAGTCAGTGC AGAGCAGAGG GGACGCAGAC AGTGCCAACA CTGAAGGTTT CACACCAAGG GCCCCACCCG CCCAGAACAA ATGGGACTCC GCCTCACCCT CCCTATTCTC AGTCCTGCAG CCTGAGCATG CTGTACCCTG AGGTGCCCTC CCACTTCCTC CTTCAGGTTC AGGCTGACAA GTAGGACCCG AGGCACTGGA GGAGCATTGA CTGTAAGTAA GCCTTTGTCA GAGCCTCCAA GGTTCAGTTC TAAGGCCTCA CACACGCTCC TTCTCTCCCC AGGCCTGTGG CCCAGCTCCT GCCCGCACTC CTGCCTGCTG CCCTGACCAG ATG CCT CTT GAG CAG AGG AGT CAG CAC TGC AAG GGC CTT GAG GCC CGA GGA GAG GCC CTG GGC CTG CAG GCT CCT GCT ACT GAG GAG CAG CAG ACC GCT TCT ACT CTA GTG GAA GTT ACC CTG GGG GAG GTG GAC TCA CCG AGT CCT CCC CAC AGT CCT CAG GGA TTC TCG ACT ACC ATC AAC TAC ACT CTT TGG AGA GAG GGC TCC AGC AAC CAA GAA GAG GAG GGG CCA CCC GAC CTG GAG TCC GAG TTC CAA GCA GCA ATC ATG GTT GAG TTG GTT CAT TTT CTG CTC CTC AAG AGG GAG CCG GTC ACA AAG GCA GAA ATG CTG GAG AGA AAT TGC CAG GAC TTC TTT CCC GTG ATC TTC TCC GAG TAC TTG CAG CTG GTC TTT GGC ATC GAG GTG GTC CCC ATC AGC CAC TTG TAC ATC CTT GTC GGC CTC TCC TAC GAT GGC CTG CTG GGC GAC AAT CCC AAG ACA GGC CTC CTG ATA ATC GTC CTG GCC ATA GAG GGC GAC TGT GCC CCT GAG GAG AAA ATC CTG AGT ATG TTG GAG GTG TTT GAG GGG AGG GAG TTC GCA CAT CCC AGG AAG CTG CTC ATG CAA GAT GAA AAC TAC CTG GAG TAC CGG CAG GTG CCC GGC GCA TGC TAC GAG TTC CTG TGG GGT CCA AGG GCC ACC AGC TAT GTG AAA GTC CTG CAC CAT ACA CTA GGA GAA CCT CAC ATT TCC TAC CCA CCC CTG CAT TTG AGA GAG GGA GAA GAG TGA GTCTCAGCAC ATGTTGCAGC CAGGGCCAGT GGGAGGGGGT GCACCTTCCA GGGCCCCATC CATTAGCTTC CACTGCCTCG GGCCCATTCC TGCCTCTTTG AAGAGAGCAG TCAGCATTCT TTTCTGTTCT GTTGGATGAC TTTGAGATTT ATCTTTCTTT TTGTTCAAAT GTTCCTTTTA ACAAATGGTT GGATGAACTT GTTTATGAAT GACAGTAGTC ACACATAGTG CTGTTTATAT TAAGAGTCCT GTTTTTTATT CAGATTGGGA AATCCATTCC TTGTCACATA ATAACAGCAG TGGAATATGT ATTTGCCTAT AATTAGCAGT AAAATACATG ATACAAGGAA CTCAAAAGAT TGCCTTATAC CTCAGTCTAT TATGTAAAAT TAAAAATATG TGCTTCTTTG AGAATGCAAA AGAAATTAAA TCTGAATAAA TCACTGGCTC ATTTCTTTAC CATTCACTCA GCATCTGCTC CCTGGTAGTA GTGGG (2) INFORMATION FOR SEQUENCE ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 662 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-21 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: GGATCCCCAT GGATCCAGGA AGAATCCAGT TCCACCCCTG CTGTGAACCC 50 AGGGAAGTCA CGGGGCCGGA TGTGACGCCA CTGACTTGCG CGTTGGAGGT 100 CAGAGAACAG CGAGATTCTC GCCCTGAGCA ACGGCCTGAC GTCGGCGGAG 150 GGAAGCAGGC GCAGGCTCCG TGAGGAGGCA AGGTAAGATG CCGAGGGAGG 200 ACTGAGGCGG GCCTCACCCC AGACAGAGGG CCCCCAATAA TCCAGCGCTG 250 CCTCTGCTGC CAGGCCTGGA CCACCCTGCA GGGGAAGACT TCTCAGGCTC 300 AGTCGCCACC ACCTCACCCC GCCACCCCCC GCCGCTTTAA CCGCAGGGAA 350 CTCTGGTGTA AGAGCTTTGT GTGACCAGGG CAGGGCTGGT TAGAAGTGCT 400 CAGGGCCCAG ACTCAGCCAG GAATCAAGGT CAGGACCCCA AGAGGGGACT 450 GAGGGTAACC CCCCCGCACC CCCACCACCA TTCCCATCCC CCAACACCAA 500 CCCCACCCCC ATCCCCCAAC ACCAAACCCA CCACCATCGC TCAAACATCA 550 ACGGCACCCC CAAACCCCGA TTCCCATCCC CACCCATCCT GGCAGAATCG 600 GAGCTTTGCC CCTGCAATCA ACCCACGGAA GCTCCGGGAA TGGCGGCCAA 650 GCACGCGGAT CC 662 (2) INFORMATION FOR SEQUENCE ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1640 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA to mRNA (ix) FEATURE: (A) NAME/KEY: cDNA MAGE-3 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: GCCGCGAGGG AAGCCGGCCC AGGCTCGGTG AGGAGGCAAG GACAGGCTGA CCTGGAGGAC CAGAGGCCCC CGGAGGAGCA AGATCTGCCA GTGGGTCTCC ATTGCCCAGC TCCTGCCCAC GTTGCCCTGA CCAGAGTCAT C ATG CCT CTT GAG CAG AGG AGT CAG CAC TGC AAG GGC CTT GAG GCC CGA GGA GAG GCC CTG GGC CTG CAG GCT CCT GCT ACT GAG GAG CAG GAG GCT GCC TCT ACT CTA GTT GAA GTC ACC CTG GGG GAG GTG GAG TCA CCA GAT CCT CCC CAG AGT CCT CAG GGA CTC CCC ACT ACC ATG AAC TAC CCT CTC TGG AGC GAG GAC TCC AGC AAC CAA GAA GAG GAG GGG CCA CCT GAC CTG GAG TCC GAG TTC CAA GCA GCA CTC GTG GCC GAG TTG GTT CAT TTT CTG CTC CTC AAG AGG GAG CCG GTC ACA AAG GCA GAA ATG CTG GGG GGA AAT TGG CAG TAT TTC TTT CCT GTG ATC TTC TCC AGT TCC TTG CAG CTG GTC TTT GGC ATC GAG GTG GAC CCC ATC GGC CAC TTG TAC ATC TTT GCC GGC CTC TCC TAC GAT GGC CTG CTG GGT GAC AAT CCC AAG GCA GGC CTC CTG ATA ATC GTC CTG GCC AGA GAG GGC GAC TGT GCC CCT GAG GAG AAA ATC CTG AGT GTG TTA GAG GTG TTT GAG GGG AGG GAA TTG GGG GAT CCC AAG AAG CTG CTC ACC CAA CAT GAA AAC TAC CTG GAG TAC CGG CAG GTC CCC GGC GCA TGT TAT GAA TTC CTG TGG GGT CCA AGG GCC ACC AGC TAT GTG AAA GTC CTG CAC CAT ATG GTA GGA GGA CCT CAC ATT TCC TAC CCA CCC CTG CAT TTG AGA GAG GGG GAA GAG TGA GTCTGAGCAC GAGTTGCAGC CAGGGCCAGT GGGAGGGGGT GCACCTTCCG GGGCCGCATC CCTTAGTTTC CACTGCCTCC GGCCCATTCT TCACTCTTTG AAGCGAGCAG TCAGCATTCT TTTCTGTTCT GTTGGATGAC TTTGAGATTA TTCTTTGTTT TTGTTCAAAT GTTCCTTTTA ACGGATGGTT GAATGAGCGT GTTTATGAAT GACAGTAGTC ACACATAGTG CTGTTTATAT TAAGAGTCTT GttTTTTACT CAAATTgGGA AATCCATTCC TTGTGACATA ATAATAGCAG TGGTAAAAGT ATTTGCTTAA GAATTAGCAA TAACATACAT GAGATAACTC AAGAAATCAA ATTCTTGCCT TGTACCTCAA TCTATTCTGT AAAATTAAAC ACCAGGATTT CCTTGACTTC TTTG (2) INFORMATION FOR SEQUENCE ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 943 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-31 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: GGATCCTCCA CCCCAGTAGA GTGGGGACCT CACAGAGTCT CCTGACAGTT CTGGGAATCC GTGGCTGCGT TTGCTGTCTG GCCCGTGGAT TCCTCTCCCA GGAATCAGGA GCTCCAGGAA AGGACTTGGT CTGAGGCAGT GTCCTCAGGT CACAGAGTAG GATAGTGCCA ACGGTGAAGG TTTGCCTTGG ATTCAAACCA CTGCCCCAGA ACACATGGAC TCCAGAGCGC CTGGCCTCAC TTCAGTCCTG CAGCCTCAGC ATGCGCTGGC CGGATGTACC CTCTCACTTC CTCCTTCAGG TTCTGAGGGG ACAGGCTGAC AGAGGCCCCC GGAGGAGCAC TGAAGGAGAA GATCTGTAAG TTAGAGCCTC CAAGGTTCCA TTCAGTACTC AGCTGAGGTC TCCCTCTCTC CCCAGGCCAG TGGGTCTCCA TTGCCCAGCT CTCCCGCCTG TTGCCCTGAC CAGAGTCATC ATG CCT CTT GAG CAG AGG AGT CAG CAC TGC AAG GGC CTT GAG GCC CGA GGA GAg GCC CTG GGC CTG CAG GCT CCT GCT ACT GAG GAG CAG GAG GCT GCC TCT AGT GTA GTT GAA GTC ACC CTG GGG GAG GTG GAG TCA CCA GAT CCT CCC CAG AGT CCT CAG GGA CTC CCC ACT ACC ATG AAC TAC CCT CTC TGG AGC GAG GAC TCC AGC AAC CAA GAA GAG GAG GGG CCA CCT GAC CTG GAG TCT GAG TTC CAA GCA GCA CTC GTG GCC AAG TTG GTT CAT TTT CTG CTC (2) INFORMATION FOR SEQUENCE ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2531 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-4 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: GGATCCAGGC CCTGCCTGGA GAAATGTGAG GGCCCTGAGT GGGATCATCC ACTCCATGAG AGTGGGGACC TCACAGAGTC TCTTGATGGC ACTGAGGGAC CGGGGCTGTG CTTACAGTCT GGCCCATGGA TTCCTCTCCT AGGAGCTCCA GGAACAAGGC TGGTCTGAGA CAGTGTCCTC AGGTTACAGA GCAGAGGATG GCCAGCAGTG AATGTTTGCC CTGAATGCAC ACCAAGGGCC CAAGACACAT AGGACTCCAA AGAGTCTGGC CTCACCTCCC CCTGCAGAAT CGACCTCTGC TGGCCGGCTA TACCCTGAGG CTTCCTCCTT CAGGTTCTGA GCAGACAGGC CAACCGGAGA TGGAGGCCAC AGAGGAGCAC CAAGGAGAAG ATCTGTAAGT TAGAGCCTCT AAGATTTGGT TCTCAGCTGA GGTCTCTCAC TCTCCGTAGG CCTGTGGGTC CCCATTGCCC AGCTTTTGCC CCTGCTGCCC TGACCAGAGT CATC ATG TCT TCT GAG CAG AAG AGT CAG CAC TGC AAG GGC GTT GAG GCC CAA GAA GAG GCC CTG GGC CTG CAG GCT CCT ACT ACT GAG GAG CAG GAG GCT GCT TCC TCT CCT CTG GTC CCT GGC ACC CTG GAG GAA GCT GAG TCA GCA GGT CCT CCC CAG AGT CCT CAG GCC TTA CCC ACT ACC ATC AGC TTC ACT TGC TGG AAT GAG GGT TCC AGC AGC CAA GAA GAG GAG GGG TCG CCT GAC GCA GAG TCC TTG TTC CGA GAA GCA AAG GTG GAT GAG TTG GCT CAT TTT CTG CTC CGC GCC AAG GAG CTG GTC ACA AAG GCA GAA ATG CTG ATC AAA AAT TAC AAG CGC TGC TTT CCT GTG ATC GCC TCC GAG TCC CTG AAG ATG ATC TTT GGC ATT GAA GTG GAC CCC GCC AGC AAC ACC TAC ACC CTT CTG GGC CTT TCC TAT GAT GGC CTG CTG GGT AAT TTT CCC AAG ACA GGC CTT CTG ATA ATC GTC CTG GCA ATG GAG GGC GAC AGC GCC TCT GAG GAG GAA GAG CTG GGT GTG ATG GGG GTG TAT GAT GGG AGG GTC TAT GGG GAG CCC AGG AAA CTG CTC ACC CAA CAG GAA AAC TAC CTG GAG TAC CGG CAG GTA CCC CCT GCG CGC TAT GAG TTC CTG TGG GGT CCA AGG GAA ACC AGC TAT GTG AAA GTC CTG GAG CAT GTG AAT GCA AGA GTT CGC ATT GCC TAC CCA TCC CTG GCT TTG TTA GAG GAG GAA GAG GGA GTC TGA GCATGAGTTG CAGCCAGGGC TGTGGGGAAG GGGCAGGGCT ATCTAACAGC CCTGTGCAGC AGCTTCCCTT GCCTCGTGTA CATTCTTCAC TCTGTTTGAA GAAAATAGTC AGTGTTCTTA TCTATTTTGT TGGATGACTT GGAGATTTAT CTCTGTTTCC GTTGAAATGT TCCTTTTAAT GGATGGTTGA ATTAACTTCA TTATGAATCG TAGTTAACGT ATATTGCTGT TAATATAGTT AGTCTTGTTT TTTATTCAGA TTGGGAAATC CGTTCTATTT GGACATAATA ACAGCAGTGG AGTAAGTATT TAGAAGTGTG GAAATAGGTG AGATAAATTA AAAGATACTT AATTCCCGCC GTCTATTCTG TAAAATTTAA AAATATATAT GCATACCTGG CTTCGTGAAT GTAAGAGAAA TTAAATCTGA ATAAATAATT ACTGGCTCAT TTCTTCTCTA TGCACTGAGC ATCTGCTCTG AGGATTAGTA GTGGAGATAC TAGGGTAAGC CAGACACACA GGGTATTAAG AGTCTAGGAG CGCGGTCATA TAATTAAGGT CCTCTAAGAT GTAGGGGAAA AGTAACGAGT GTGGGTATGG GAGAGTGGTC GGGTGTAAAT TCCCTGTGTG GGGCCTTTTG AACTGCATTT TCTTCTGAGG GATCTGATTC TAATGAAGCT AGGGCCAGAT TCTCAGAGGG AGAGGGAAAA GCCCAGATTG TCTGAGCAGT TCCTTTGTGA CAATGGATGA ACAGAGAGGA GCCTCTACCT 2528 GGG 2531 (2) INFORMATION FOR SEQUENCE ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2531 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-41 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: GGATCCAGGC CCTGCCTGGA GAAATGTGAG GGCCCTGAGT GAACACAGTG 50 GGGATCATCC ACTCCATGAG AGTGGGGACC TCACAGAGTC CAGCCTACCC 100 TCTTGATGGC ACTGAGGGAC CGGGGCTGTG CTTACAGTCT GCACCCTAAG 150 GGCCCATGGA TTCCTCTCCT AGGAGCTCCA GGAACAAGGC AGTGAGGCCT 200 TGGTCTGAGA CAGTGTCCTC AGGTTACAGA GCAGAGGATG CACAGGCTGT 250 GCCAGCAGTG AATGTTTGCC CTGAATGCAC ACCAAGGGCC CCACCTGCCA 300 CAAGACACAT AGGACTCCAA AGAGTCTGGC CTCACCTCCC TACCATCAAT 350 CCTGCAGAAT CGACCTCTGC TGGCCGGCTA TACCCTGAGG TGCTCTCTCA 400 CTTCCTCCTT CAGGTTCTGA GCAGACAGGC CAACCGGAGA CAGGATTCCC 450 TGGAGGCCAC AGAGGAGCAC CAAGGAGAAG ATCTGTAAGT AAGCCTTTGT 500 TAGAGCCTCT AAGATTTGGT TCTCAGCTGA GGTCTCTCAC ATGCTCCCTC 550 TCTCCGTAGG CCTGTGGGTC CCCATTGCCC AGCTTTTGCC TGCACTCTTG 600 CCTGCTGCCC TGAGCAGAGT CATC 624 ATG TCT TCT GAG CAG AAG AGT CAG CAC TGC AAG CCT GAG GAA 666 GGC GTT GAG GCC CAA GAA GAG GCC CTG GGC CTG GTG GGT GCG 708 CAG GCT CCT ACT ACT GAG GAG CAG GAG GCT GCT GTC TCC TCC 750 TCC TCT CCT CTG GTC CCT GGC ACC CTG GAG GAA GTG CCT GCT 792 GCT GAG TCA GCA GGT CCT CCC CAG AGT CCT CAG GGA GCC TCT 834 GCC TTA CCC ACT ACC ATC AGC TTC ACT TGC TGG AGG CAA CCC 876 AAT GAG GGT TCC AGC AGC CAA GAA GAG GAG GGG CCA AGC ACC 918 TCG CCT GAC GCA GAG TCC TTG TTC CGA GAA GCA CTC AGT AAC 960 AAG GTG GAT GAG TTG GCT CAT TTT CTG CTC CGC AAG TAT CGA 1002 GCC AAG GAG CTG GTC ACA AAG GCA GAA ATG CTG GAG AGA GTC 1044 ATC AAA AAT TAC AAG CGC TGC TTT CCT GTG ATC TTC GGC AAA 1086 GCC TCC GAG TCC CTG AAG ATG ATC TTT GGC ATT GAC GTG AAG 1128 GAA GTG GAC CCC ACC AGC AAC ACC TAC ACC CTT GTC ACC TGC 1170 CTG GGC CTT TCC TAT GAT GGC CTG CTG GGT AAT AAT CAG ATC 1212 TTT CCC AAG ACA GGC CTT CTG ATA ATC GTC CTG GGC ACA ATT 1254 GCA ATG GAG GGC GAC AGC GCC TCT GAG GAG GAA ATC TGG GAG 1296 GAG CTG GGT GTG ATG GGG GTG TAT GAT GGG AGG GAG CAC ACT 1338 GTC TAT GGG GAG CCC AGG AAA CTG CTC ACC CAA GAT TGG GTG 1380 CAG GAA AAC TAC CTG GAG TAC CGG CAG GTA CCC GGC AGT AAT 1422 CCT GCG CGC TAT GAG TTC CTG TGG GGT CCA AGG GCT CTG GCT 1464 GAA ACC AGC TAT GTG AAA GTC CTG GAG CAT GTG GTC AGG GTC 1506 AAT GCA AGA GTT CGC ATT GCC TAC CCA TCC CTG CGT GAA GCA 1548 GCT TTG TTA GAG GAG GAA GAG GGA GTC TGA 1578 GCATGAGTTG CAGCCAGGGC TGTGGGGAAG GGGCAGGGCT GGGCCAGTGC 1628 ATCTAACAGC CCTGTGCAGC AGCTTCCCTT GCCTCGTGTA ACATGAGGCC 1678 CATTCTTCAC TCTGTTTGAA GAAAATAGTC AGTGTTCTTA GTAGTGGGTT 1728 TCTATTTTGT TGGATGACTT GGAGATTTAT CTCTGTTTCC TTTTACAATT 1778 GTTGAAATGT TCCTTTTAAT GGATGGTTGA ATTAACTTCA GCATCCAAGT 1828 TTATGAATCG TAGTTAACGT ATATTGCTGT TAATATAGTT TAGGAGTAAG 1878 AGTCTTGTTT TTTATTCAGA TTGGGAAATC CGTTCTATTT TGTGAATTTG 1928 GGACATAATA ACAGCAGTGG AGTAAGTATT TAGAAGTGTG AATTCACCGT 1978 GAAATAGGTG AGATAAATTA AAAGATACTT AATTCCCGCC TTATGCCTCA 2028 GTCTATTCTG TAAAATTTAA AAATATATAT GCATACCTGG ATTTCCTTGG 2078 CTTCGTGAAT GTAAGAGAAA TTAAATCTGA ATAAATAATT CTTTCTGTTA 2128 ACTGGCTCAT TTCTTCTCTA TGCACTGAGC ATCTGCTCTG TGGAAGGCCC 2178 AGGATTAGTA GTGGAGATAC TAGGGTAAGC CAGACACACA CCTACCGATA 2228 GGGTATTAAG AGTCTAGGAG CGCGGTCATA TAATTAAGGT GACAAGATGT 2278 CCTCTAAGAT GTAGGGGAAA AGTAACGAGT GTGGGTATGG GGCTCCAGGT 2328 GAGAGTGGTC GGGTGTAAAT TCCCTGTGTG GGGCCTTTTG GGCTTTGGGA 2378 AACTCCATTT TCTTCTGAGG GATCTGATTC TAATGAAGCT TGGTGGGTCC 2428 AGGGCCAGAT TCTCAGAGGG AGAGGGAAAA GCCCAGATTG GAAAAGTTGC 2478 TCTGAGCGGT TCCTTTGTGA CAATGGATGA ACAGAGAGGA GCCTCTACCT 2528 GGG 2531 (2) INFORMATION FOR SEQUENCE ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1068 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA to mRNA (ix) FEATURE: (A) NAME/KEY: cDNA MAGE-4 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: G GGG CCA AGC ACC TCG CCT GAC GCA GAG TCC GAA GCA CTC AGT AAC AAG GTG GAT GAG TTG GCT CTC CGC AAG TAT CGA GCC AAG GAG CTG GTC ACA ATG CTG GAG AGA GTC ATC AAA AAT TAC AAG CGC GTG ATC TTC GGC AAA GCC TCC GAG TCC CTG AAG GGC ATT GAC GTG AAG GAA GTG GAC CCC GCC AGC ACC CTT GTC ACC TGC CTG GGC CTT TCC TAT GAT GGT AAT AAT CAG ATC TTT CCC AAG ACA GGC CTT GTC CTG GGC ACA ATT GCA ATG GAG GGC GAC AGC GAG GAA ATC TGG GAG GAG CTG GGT GTG ATG GGG GGG AGG GAG CAC ACT GTC TAT GGG GAG CCC AGG ACC CAA GAT TGG GTG CAG GAA AAC TAC CTG GAG GTA CCC GGC AGT AAT CCT GCG CGC TAT GAG TTC CCA AGG GCT CTG GCT GAA ACC AGC TAT GTG AAA CAT GTG GTC AGG GTC AAT GCA AGA GTT CGC ATT TCC CTG CGT GAA GCA GCT TTG TTA GAG GAG GAA TGAGCATGAG TTGCAGCCAG GGCTGTGGGG AAGGGGCAGG TGCATCTAAC AGCCCTGTGC AGCAGCTTCC CTTGCCTCGT GCCCATTCTT CACTCTGTTT GAAGAAAATA GTCAGTGTTC GTTTCTATTT TGTTGGATGA CTTGGAGATT TATCTCTGTT ATTGTTGAAA TGTTCCTTTT AATGGATGGT TGAATTAACT AGTTTATGAA TCGTAGTTAA CGTATATTGC TGTTAATATA AAGAGTCTTG TTTTTTATTC AGATTGGGAA ATCCGTTCTA TTGGGACATA ATAACAGCAG TGGAGTAAGT ATTTAGAAGT (2) INFORMATION FOR SEQUENCE ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2226 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-5 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: GGATCCAGGC CTTGCCAGGA GAAAGGTGAG GGCCCTGTGT GAGCACAGAG 50 GGGACCATTC ACCCCAAGAG GGTGGAGACC TCACAGATTC CAGCCTACCC 100 TCCTGTTAGC ACTGGGGGCC TGAGGCTGTG CTTGCAGTCT GCACCCTGAG 150 GGCCCATGCA TTCCTCTTCC AGG GCTCCA GGAAACAGAC ACTGAGGCCT 200 TGGTCTGAGG CCGTGCCCTC AGGTCACAGA GCAGAGGAGA TGCAGACGTC 250 TAGTGCCAGC AGTGAACGTT TGCCTTGAAT GCACACTAAT GGCCCCCATC 300 GCCCCAGAAC ATATGGGACT CCAGAGCACC TGGCCTCACC TCAGTCCTGC AGAATCAGCC TCTGCTTGCT TGTGTACCCT CTCACTTTTT CCTTCAGGTT CTCAGGGGAC AGGCTGACCA GAAGCTCCAG AGGATCCCCA GGAGGCCCTA GAGGAGCACC ATCTGTAAGT AAGCCTTTGT TAGAGCCTCC AAGGTTCAGT GGCTTCTCAC ATGCTCCCTC TCTCTCCAGG CCAGTGGGTC AGCTCCTGCC CACACTCCTG CCTGTTGCGG TGACCAGAGT ATG TCT CTT GAG CAG AAG AGT CAG CAC TGC AAG CTC CTC TGG TCC CAG GCA CCC TGG GGG AGG TGC GGT CAC CAG GTC CTC TCA AGA GTC CTC AGG GAG TCC CCA CTG CCA TCG ATT TCA CTC TAT GGA GGC AGG GCT CCA GCA ACC AAG AAG AGG AGG GGC CAA CTG ACC CAG AGT CTG TGT TCC GAG CAG CAC TCA TGG CTG ACT TGA TTCATTTTCT GCTCCTCAAG TATTAAGTCA AGGAGCTGGT GAAATGCTGG AGAGCGTCAT CAAAAATTAC AAGCGCTGCT CTTCGGCAAA GCCTCCGAGT CCTTGCAGCT GGTCTTTGGC AGGAAGCGGA CCCCACCAGC AACACCTACA CCCTTGTCAC CTCCTATGAT GGCCTGCTGG TTGATAATAA TCAGATCATG GCCTCCTGAT AATCGTCTTG GGCATGATTG CAATGGAGGG CCTGAGGAGA AAATCTGGGA GGAGCTGAGT GTGATGAAGG GAGGGAGCAC AGTGTCTGTG GGGAGCCCAG GAAGCTGCTC TGGTGCAGGA AAACTACCTG GAGTACCGGC AGGTGCCCAG ATATGCTATG AGTTACTGTG GGGTCCAAGG GCACTCGCTG CTGGAGCACG TGGTCAGGGT CAATGCAAGA GTTCTCATTT CCTGCGTGAA GCAGCTTTGA GAGAGGAGGA AGAGGGAGTC CTGCAGCCAG GGCCACTGCG AGGGGGGCTG GGCCAGTGCA CTCCGTCCAG TAGTTTCCCC TGCCTTAATG TGACATGAGG TCTCTTTGAA GAGAGCAGTC AACATTCTTA GTAGTGGGTT TGGATGACTT TGAGATTTGT CTTTGTTTCC TTTTGGAATT TTCTTTTAAT GGGTGGTTGA ATGAACTTCA GCATTCAAAT CAGTAGTCAC ACATAGTGCT GTTTATATAG TTTAGGAGTA TTTTTATTCA GATTGGGAAA TCCATTCCAT TTTGTGAATT TACAGCAGTG GAATAAGTAT TCATTTAGAA ATGTGAATGA TGATGACATA AAGAAATTAA AAGATATTTA ATTCTTGCTT TATTCGGTAA AATTTTTTTT AAAAAATGTG CATACCTGGA TTCTTTGAGA ATGTAAGACA AATTAAATCT GAATAAATCA TCACTGGCTC ATTTATTCTC TATGCACTGA GCATTTGCTC CCTGGGTTAA TAGTGGAGAT GCTAAGGTAA GCCAGACTCA CAGGGTAGTA AAGTCTAGGA GCAGCAGTCA TATAATTAAG GCCCTCTAAG ATGTAGAG (2) INFORMATION FOR SEQUENCE ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2305 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-51 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: GGCTTCTCAC ATGCTCCCTC TCTCTCCAGG CCAGTGGGTC AGCTCCTGCC CACACTCCTG CCTGTTGCGG TGACCAGAGT ATG TCT CTT GAG CAG AAG AGT CAG CAC TGC AAG GGC CTT GAC ACC CAA GAA GAG CCC TGG GCC TGG AGG CTG CCA CTA CTG AGG AGC AGG AGG CTG TGT CTC CTC TGG TCC CAG GCA CCC TGG GGG AGG TGC GGT CAC CAG GTC CTC TCA AGA GTC CTC AGG GAG TCC CCA CTG CCA TCG ATT TCA CTC TAT GGA GGC AGG GCT CCA GCA ACC AAG AAG AGG AGG GGC CAA CTG ACC CAG AGT CTG TGT TCC GAG CAG CAC TCA TGG CTG ACT TGA TTCATTTTCT GCTCCTCAAG TATTAAGTCA AGGAGCCGGT GAAATGCTGG AGAGCGTCAT CAAAAATTAC AAGCGCTGCT CTTCGGCAAA GCCTCCGAGT CCTTGCAGCT GGTCTTTGGC AGGAAGCGGA CCCCACCAGC AACACCTACA CCCTTGTCAC CTCCTATGAT GGCCTGGTGG TTTAATCAGA TCATGCCCAA CTGATAATCG TCTTGGGCAT GATTGCAATG GAGGGCAAAT GGAGAAAATC TGGGAGGAGC TGGGTGTGAT GAAGGTGTAT AGCACAGTGT CTGTGGGGAG CCCAGGAAGC TGCTCACCCA CAGGAAAACT ACCTGGAGTA CCGCAGGTGC CCAGCAGTGA TATGAGTTAC TGTGGGGTCC AAGGGCACTC GCTGCTTGAA CACGTGGTCA GGGTCAATGC AAGAGTTCTC ATTTCCTACC TGAAGCAGCT TTGAGAGAGG AGGAAGAGGG AGTCTGAGCA CCAGGGCCAC TGCGAGGGGG GCTGGGCCAG TGCACCTTCC CCAGTAGTTT CCCCTGCCTT AATGTGACAT GAGGCCCATT TGAAGAGAGC AGTCAACATT CTTAGTAGTG GGTTTCTGTT ACTTTGAGAT TTGTCTTTGT TTCCTTTTGG AATTGTTCAA TAATGGGTGG TTGAATGAAC TTCAGCATTC AAATTTATGA TCACACATAG TGCTGTTTAT ATAGTTTAGG AGTAAGAGTC TTCAGATTGG GAAATCCATT CCATTTTGTG AATTGGGACA AGTGGAATAA GTATTCATTT AGAAATGTGA ATGAGCAGTA GATAAAGAAA TTAAAAGATA TTTAATTCTT GCCTTATACT GGTAAAATTT TTTTTTAAAA ATGTGCATAC CTGGATTTCC TGAGAATGTA AGACAAATTA AATCTGAATA AATCATTCTC GGCTCATTTA TTCTCTATGC ACTGAGCATT TGCTCTGTGG GTTAATAGTG GAGATGCTAA GGTAAGCCAG ACTCACCCCT TAGTAAAGTC TAGGAGCAGC AGTCATATAA TTAAGGTGGA CTAAGATGTA GAG (2) INFORMATION FOR SEQUENCE ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 225 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ϋ) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: MAGE-6 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: TAT TTC TTT CCT GTG ATC TTC AGC AAA GCT TCC GAT TCC TTG 42 CAG CTG GTC TTT GGC ATC GAG CTG ATG GAA GTG GAC CCC ATC 84 GGC CAC GTG TAC ATC TTT GCC ACC TGC CTG GGC CTC TCC TAC 126 GAT GGC CTG CTG GGT GAC AAT CAG ATC ATG CCC AGG ACA GGC 168 TTC CTG ATA ATC ATC CTG GCC ATA ATC GCA AGA GAG GGC GAC 210 TGT GCC CCT GAG GAG 225 (2) INFORMATION FOR SEQUENCE ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1947 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA ' (ix) FEATURE: (A) NAME/KEY: MAGE-7 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: TGAATGGACA ACAAGGGCCC CACACTCCCC AGAACACAAG GAGCCCAGCC TCACCTTCCC TACTGTCAGT CCTGCAGCCT TGGCCGGCTG TACCCTGAGG TGCCCTCTCA CTTCCTCCTT GCGGACAGGC CGGCCAGGAG GTCAGAAGCC CCAGGAGGCC ACCGAAGGAG AAGATCTGTA AGTAGGCCTT TGTTAGGGCC GGTTCACAAA TGAGGCCCCT CACAAGCTCC TTCTCTCCCC GTTCCTCCCC ATCGCCCAGC TGCTGCCCGC ACTCCAGCCT CCAGAGTCAT CATGTCTTCT GAGCAGAGGA GTCAGCACTG GATGCCTTGA GGCCCAAGGA CAGGAGGCTC TGGGCCTGGT GCTCCCGCCA CCGAGGAGCA CGAGGCTGCC TCCTCCTTCA AGGCACCCTG GAGGAGGTGC CTGCTGCTGG GTCCCCCAGT GTCTCAGGGT TCCTCCTTTT CCCTGACCAT CAGCAACAAC GCCAATCCAG TGAGGGCACC AGCAGCCGGG AAGAGGAGGG TAGACACACC CCGCTCACCT GGCGTCCTTG TTCCA ATG GGA AGG TGG CTG AGT TGG TTC GCT TCC TGC ATC GAG TCA AGG AGC TGG TCA CAA AGG CAG AAA GTG TCA TCA AAA ATT ACA AGC ACT AGT TTC CTT GGC AAA GCC TCA GAG TGC ATG CAG GTG ATG TTT ATG AAG GAA GTG GAC CCC GCG GCC ACT CCT ACG CCT GCT TGG GCC TCT CCT ACA ATG GCC TGC TGG AGA GCA TGC CCG AGA CCG GCC TTC TGA TTATGGTCTT GACCATGATC TTAATGGAGG GCCACTGTGC GCAATCTGGG AAGCGTTGAG TGTAATGGTG TATGATGGGA TCTTTGGGCA GCTGAGGAAG CTGCTCACCC AAGATTGGGT TACCTGCAAT ACCGCCAGGT GCCCAGCAGT GATCCCCCGT CCTGTGGGGT CCAAGGGCCC TCATTGAAAC CAGCTATGTG AGTATGCAGC CAGGGTCAGT ACTAAAGAGA GCATTTCCTA CATGAAGAGG CTTTGGGAGA GGAGGAAGAG GGAGTCTGAG AGCCAGGGCC AGTGGGGCAG ATTGGGGGAG GGCCTGGGCA CACACATCCA CCACCTTCCC TGTCCTGTTA CATGAGGCCC CTGTGTTTGA AGAGAGCAGT CAATGTTCTC AGTAGCGGGG GTGTGAGGGA ATACAAGGTG GACCATCTCT CAGTTCCTGT GATTTGGAGG TTTATCTTTG TTTCCTTTTG CAGTCGTTCA TTAATGGATG GTGTAATGAA CTTCAACATT CATTTCATGT GCAGACTTAC TGTTTTTTAT ATAGTTAAAA GTAAGTGCAT TTATGTAAGA AAATCTATGT TATTTCTTGA ATTGGGACAA CAGAGGATTA AGTACCTTTT ATAATGTGAA AGAACAAAGC GTGAGATAAA GAAATAAAGA AATTAAATTG GCTGGGCACG CCTGTAATCC CAGCACTTTA GGAGGCAGAG GCACGGGGAT GGAGATCGAG ACCATTCTGG CTAACACAGT GAAACACCAT AATACAAAAC TTAGCCGGGC GTGGTGGCGG GTG (2) INFORMATION FOR SEQUENCE ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1810 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ϋ) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-8 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: GAGCTCCAGG AACCAGGCTG TGAGGTCTTG GTCTGAGGCA GTATCTTCAA 50 TCACAGAGCA TAAGAGGCCC AGGCAGTAGT AGCAGTCAAG CTGAGGTGGT 100 GTTTCCCCTG TATGTATACC AGAGGCCCCT CTGGCATCAG ACCCCACAGT TCCTGGCCCT ACCAGCCCTT TTGTCAGTCC GCCTTTGCCA GGAGGCTGCA CCCTGAGATG CCCTCTCAAT GGTTCGCAGA GAACAGGCCA GCCAGGAGGT CAGGAGGCCC CTGAAGAAGA CCTGTAAGTA GACCTTTGTT AGGGCATCCA CCCAGCTGAG GCCTCTCACA CGCTTCCTCT CTCCCCAGGC CAATTGCCCA GCTCCGGCCC ACACTCTCCT GCTGCCCTGA C ATG CTT CTT GGG CAG AAG AGT CAG CGC TAC AAG GGC CTT CAG GCC CAA GGA GAG GCA CCA GGG CTT CAG ATT CCC ACA GCT GAG GAG CAG AAG GCT GCA TCT ACT CTG ATC ATG GGA ACC CTT GAG GAG GTG GGG TCA CCA AGT CCT CCC CAG AGT CCT GAG GGT TCC CTG ACT GTC ACC GAC AGC ACT CTG TGG AGC GAG GGT TCC AGC AGC AAT GAA GAG GAG GGG CCA CCG GAC CCA GCT CAC CTG GAG TCC CTG TTC CGG GAT GAG AAA GTG GCT GAG TTA GTT CGT TTC CTG TAT CAA ATT AAG GAG CCG GTC ACA AAG GCA GAA AGT GTC ATC AAA AAT TAC AAG AAC CAC TTT CCT AGC AAA GCC TCT GAG TGC ATG CAG GTG ATC TTT GTG AAG GAA GTG GAC CCT GCC GGC CAC TCC TAC ACC TGC CTG GGC CTC TCC TAT GAT GGC CTG CTG CAG AGT ACG CCC AAG ACC GGC CTC CTG ATA ATC ATG ATC TTA ATG GAG GGC AGC CGC GCC CCG GAG TGG GAA GCA TTG AGT GTG ATG GGG GCT GTA TGA TGGGAGGGAG CACAGTGTCT ATTGGAAGCT CAGGAAGCTG AGTGGGTGCA GGAGAACTAC CTGGAGTACC GCCAGGCGCC CCTGTGCGCT ACGAGTTCCT GTGGGGTCCA AGGGCCCTTG CTATGTGAAA GTCCTGGAGC ATGTGGTCAG GGTCAATGCA TTTCCTACCC ATCCCTGCAT GAAGAGGCTT TGGGAGAGGA TGAGCAGGAG TTGCAGCTAG GGCCAGTGGG GCAGGTTGTG GGCCAGTGCA CGTTCCAGGG CCACATCCAC CACTTTCCCT ATGAGGCCCA TTCTTCACTC TGTGTTTGAA GAGAGCAGTC GTAGTGGGGA GCATGTTGGG TGTGAGGGAA CACAGTGTGG AGTTCCTGTT CTATTGGGCG ATTTGGAGGT TTATCTTTGT AATTGTTCCA ATGTTCCTTC TAATGGATGG TGTAATGAAC ATTTTATGTA TGACAGTAGA CAGACTTACT GCTTTTTATA GTAAGAGTCT TGCTTTTCAT TTATACTGGG AAACCCATGT ATTC (2) INFORMATION FOR SEQUENCE ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1412 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-9 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21: TCTGAGACAG TGTCCTCAGG TCGCAGAGCA GAGGAGACCC AGCAGTGAAG GTGAAGTGTT CACCCTGAAT GTGCACCAAG GCCCCAGCAC ACATGGGACC CCATAGCACC TGGCCCCATT TCACTCATAG AGCCTTGATC TCTGCAGGCT AGCTGCACGC TCTCACTTCC TCCCTCAGGT TCTCGGGACA GGCTAACCAG GCCCCAAGAG GCCCCAGAGC AGCACTGACG AAGACCTGTA TGTTAGAACC TCCAAGGTTC GGTTCTCAGC TGAAGTCTCT CTCTCTCCCC AGGCCTGTGG GTCTCCATCG CCCAGCTCCT CTGACTGCTG CCCTGACCAG AGTCATC ATG TCT CTC GAG CAG AGG AGT CCG CAC TGC AAG GAC CTT GAA GCC CAA GGA GAG GAC TTG GGC CTG CAG GAA CCC ACA GGC GAG GAG GAG GAG ACT ACC GAC AGC AAG GAG GAG GAG GTG TCT GCT GCT GGG CCT CCC CAG AGT CCT CAG GGA GGC GCT TCC TCC GTC TAC TAC ACT TTA TGG AGC CAA TTC GAT GAG AGT CAA GAA GAG GAA GAG CCA AGC TCC TCG GTC CAG CTG GAG TTC ATG TTC CAA GAA GCA CTG AAA GCT GAG TTG GTT CAT TTC CTG CTC CAC AAA TAT GAG CCG GTC ACA AAG GCA GAA ATG CTG GAG AGC AAT TAC AAG CGC TAC TTT CCT GTG ATC TTC GGC GAG TTC ATG CAG GTG ATC TTT GGC ACT GAT GTG GAC CCC GCC GGC CAC TCC TAC ATC CTT GTC ACT CTC TCG TGC GAT AGC ATG CTG GGT GAT GGT CAT AAG GCC GCC CTC CTG ATC ATT GTC CTG GGT GTG AAA GAC AAC TGC GCC CCT GAA GAG GTT ATC TGG AGT GTG ATG GGG GTG TAT GTT GGG AAG GAG CAC GGG GAG CCC AGG AAG CTG CTC ACC CAA GAT TGG AAC TAC CTG GAG TAC CGG CAG GTG CCC GGC AGT CAC TAC GAG TTC CTG TGG GGT TCC AAG GCC CAC AGC TAT GAG AAG GTC ATA AAT TAT TTG GTC ATG AGA GAG CCC ATC TGC TAC CCA TCC CTT TAT GAA GGA GAG GAG CAA GAG GGA GTC TGA GCACCAGCCG CAGCCGGGGC CAAAGTTTGT GGGGTCA (2) INFORMATION FOR SEQUENCE ID NO: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 920 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-10 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22: ACCTGCTCCA GGACAAAGTG GACCCCACTG CATCAGCTCC CTGTCAGTCC TGGAGCCTTG GCCTCTGCCG GCTGCATCCT CTCTCACTTC CTTCTTCAGG TTCTCAGGGG ACAGGGAGAG AGAGCTGTGG GACACCACAG AGCAGCACTG AAGGAGAAGA GGCCTTTGTT AGAACCTCCA GGGTGTGGTT CTCAGCTGTG CCCTCCCTCT CTCCCCAGGC CTGTGGGTCC CCATCGCCCA ACACTCCCAC CTGCTACCCT GATCAGAGTC ATC ATG CCT CGA GCT CCA AAG CGT CAG CGC TGC ATG GAT CTT CAA TCC CAA AGT GAG ACA CAG GGC CTC CAG GCT CCC CTG GCT GTG GAG GAG GAT GCT TCA TCC ACC AGC TCC TCT TTT CCA TCC TCT TTT CCC TCT TCC TCC TCC TCC TCC TGC TAT CCT CTA ATA CCA GAG GAG GTT TCT GCT GAT GAT GAG ACA CCA CAG AGT GCT CAG ATA GCC TGC TCC TCC CCC TCG TCC CTT CCA TTA GAT CAA TCT GAT GAG GGC TCC AAG GAG GAG AGT CCA AGC ACC CTA CAG GTC CTG GAG TCT TTA CCC AGA AGT GAG ATA GAT GAA AAG TTG GTG CAG TTT CTG CTC TTC AAG TAT CAA ATG ATC ACA AAG GCA GAA ATA CTG GAG AGT GTC ATA GAA GAC CAC TTC CCT TTG TTG TTT AGT GAA GCC ATG CTG CTG GTC TTT GGC ATT GAT GTA AAG GAA (2) INFORMATION FOR SEQUENCE ID NO: 23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1107 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: MAGE-11 gene (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23: AGAGAACAGG CCAACCTGGA GGACAGGAGT CCCAGGAGAA CACTGGAGGA GAACAAGTGT AAGTAGGCCT TTGTTAGATT CATATCTCAT CTGAGTCTGT TCTCACGCTC CCTCTCTCCC GGCCCCATCA CCCAGATATT TCCCACAGTT CGGCCTGCTG AGTCATCATG CCTCTTGAGC AAAGAAGTCA GCACTGCAAG CCTTCAGGCC CAAGAAGAAG ACCTGGGCCT GGTGGGTGCA AAGCTGAGGA GCAGGAGGCT GCCTTCTTCT CCTCTACTCT ACTCTAGAGG AGTTGCCTGC TGCTGAGTCA CCAAGTCCTC TCAGGAAGAG TCCTTCTCTC CCACTGCCAT GGATGCCATC TATCTGATGA GGGCTCTGGC AGCCAAGAAA AGGAGGGGCC CCTGACCTGA TAGACCCTGA GTCCTTTTCC CAAGATATAC GATAATTGAT TTGGTTCATT TATTCTCCGC AAGTATCGAG GATCACAAAG GCAGAA ATG CTG GGG AGT GTC ATC AAA AAT TAT GAG GAC GAG ATA TTT AGG GAA GCC TCT GTA TGC ATG CAA GGC ATT GAT GTG AAG GAA GTG GAC CCC ACT AGC GTC CTT GTC ACC TCC CTC AAC CTC TCT TAT GAT TGT AAT GAG CAG AGC ATG CCC AAG TCT GGC CTC GTC CTG GGT GTA ATC TTC ATG GAG GGG AAC TGC GAG GTT ATG TGG GAA GTC CTG AGC ATT ATG GGG GGA AGG GAG CAC TTC CTC TTT GGG GAG CCC AAG ACC CAA AAT TGG GTG CAG GAA AAG TAC CTG GTG GTG CCC GGC ACT GAT CCT GCA TGC TAT GAG TTC CCA AGG GCC CAC GCT GAG ACC AGC AAG ATG AAA TAC ATA GCC AAT GCC AAT GGG AGG GAT CC (2) INFORMATION FOR SEQUENCE ID NO: 24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2150 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: smage-I (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24: TCTGTCTGCA TATGCCTCCA CTTGTGTGTA GCAGTCTCAA CTCTACAGAC CTCTGTCTGT GTCTGGCACC CTAAGTGGCT ACAGGTTTCT GCCCCTGCAT GGAGCTTAAA TAGATCTTTC TATACCCCTG CATTGTAAGT TTAAGTGGCT TTATGTGGAT GCCCTTGTAT GCAGGCCTAA GTTTTTCTGT CTGCTTAACC AAGCTAGTGA AAGATCTAAC CCACTTTTGG AAGTCTGAAA ATGCAGTGGC CTAACAAGTT TTAATTTCTT CCACAGGGTT AGCTTGATCC ACGAGTTCAG AAGTCCTGGT ATGTTCCTAG ATG TTC TCC TGG AAA GCT TCA AAA GCC AGG TCT CCA AGG TAT TCT CTA CCT GGT AGT ACA GAG GTA TGT CAT TCT TAT CCT TCC AGA TTC CTG TCT GCC ACT TCA GCC CTG AGC ACA GTC AAC ATG CCT AGG AGT AAG ACC CGC TCC CGT GCA AAA CGA CAG CAG GAG GTT CCA GTA GTT CAG CCC ACT GCA GAG GAA TCT CCT GTT GAC CAG AGT GCT GGG TCC AGC TTC TCT GCT CCT CAG GGT GTG AAA ACC CCT GGA TCT GGT GTA TCC TGC ACA GGC TCT GGT ATA GGT GGT GCT GTC CTG CCT GAT ACA AAA AGT TCA GAT GGC GGG ACT TCC ATT CAG CAC ACA CTG AAA GAT CCT AAG GCT AGT GTG CTG ATA GAA TTC CTG CTA GAT ATG AAA GAA GCA GTT ACA AGG AGT GAA ATG CTG AAC AAG AAG TAT AAG GAG CAA TTC CCT GAG ATC ACT TCT GCA CGC CTA GAA TTA GTC TTT GGT CTT GAA ATT GAT CCC AGC ACT CAT TCC TAT TTG CTG CTG GGT CTT TCC ACT GAG GGA AGT TTG AGT AGT TTG CCT AGG ACA GGT CTC CTA ATG TCT GTC CTA TTC ATG AAG GGT AAC CGT GCC ACT GAG CAA GAG TTT CTG CAT GGA GTG GGG GTA TAT GCT GGG AAG ATC TTT GGC GAG CCT GAG GAG TTT ATA AGA GAT GAA AAT TAC CTG GAG TAC CGC CAG GTA CCT GGC CCA AGC TAT GAG TTC CTG TGG GGA CCC AGA GCC ACA ACC AAG ATG AAA GTC CTG GAA GTT TTA GCT GGC ACA GTC CCT AGT GCC TTC CCT AAT CTC TAC CTT AGA GAT CAG GCA GGA GGG GTG CCA AGA AGG GGC AAG GGT GTT CAT TCC AAG GCC CCA TCC CAA AAC ATG TAG TTGAGTCTGT TCTGTTGTGT TTGAAAAACA GTCAGGCTCC AGAGTTCATA GCCTACCAGA ACCAACATGC ATCCATTCTT ACATTAGTAG AATGGAGGCT ATTTTTGTTA CTTTTCAAAT CTAAACAGTG CTTTTTGCCA TGCTTCTTGT TAACTGCATA TGTCACTTGT CAGATTAGGA CTTGTTTTGT TATTTGCAAC ACATTATTTT GTTTTTACTA AAACATTGTG TAACATTGCA GATTGTCATG GCAATGTGAT ATCATACAGT GGTGAAACAA GGAAAGTTTA TATTGTTAAT TTTGAAAATT TTATGAGTGT TACTTTTTTC TTTTTTGTAT AATGCTAAGT GAAATAAAGT GACTTTACTC AAATTCATTA GAAAGTAAAT CGTAAAACTC TTATTTTCTT CAATTATGAA TTAAGCATTG GTTATCTGGA GTAGCACAGG ATCTAGTATG AAATGTATCT AGTATAGGCA GTTATCAGAG TCT (2) INFORMATION FOR SEQUENCE ID NO: 25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2099 base pairs (B) TYPE: nucleic acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: genomic DNA (ix) FEATURE: (A) NAME/KEY: smage-II (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25: (2) INFORMATION FOR SEQUENCE ID NO: 26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26: Glu Ala Asp Pro Thr Gly His Ser Tyr 5 (2) INFORMATION FOR SEQUENCE ID NO: 27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27: TGGAGGACCA GAGGCCCCC 19 (2) INFORMATION FOR SEQUENCE ID NO: 28: (i) SEQUENCE'CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28: GGACGATTAT CAGGAGGCCT GC 22 (2) INFORMATION FOR SEQUENCE ID NO: 29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29: GAGCAGACAG GCCAACCG 18 (2) INFORMATION FOR SEQUENCE ID NO: 30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30: AAGGACTCTG CGTCAGGC 18 (2) INFORMATION FOR SEQUENCE ID NO: 31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31: CTAGAGGAGC ACCAAAGGAG AAG 23 (2) INFORMATION FOR SEQUENCE ID NO: 32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32: TGCTCGGAAC ACAGACTCTG G 21 (2) INFORMATION FOR SEQUENCE ID NO: 33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33: TGGAGGACCA GAGGCCCCC 19 (2) INFORMATION FOR SEQUENCE ID NO: 34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34: CAGGATGATT ATCAGGAAGC CTGT 24 (2) INFORMATION FOR SEQUENCE ID NO: 35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35: CAGAGGAGCA CCGAAGGAGA A 21 (2) INFORMATION FOR SEQUENCE ID NO: 36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36: CAGGTGAGCG GGGTGTGTC 19 (2) INFORMATION FOR SEQUENCE ID NO: 37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37: CCCCAGAGAA GCACTGAAGA AG 22 (2) INFORMATION FOR SEQUENCE ID NO: 38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38: GGTGAGCTGG GTCCGGG 17 (2) INFORMATION FOR SEQUENCE ID NO: 39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39: CCCCAGAGCA GCACTGACG 19 (2) INFORMATION FOR SEQUENCE ID NO: 40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40: CAGCTGAGCT GGGTCGACC 19 (2) INFORMATION FOR SEQUENCE ID NO: 41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41: CACAGAGCAG CACTGAAGGA G 21 (2) INFORMATION FOR SEQUENCE ID NO: 42: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42: CTGGGTAAAG ACTCACTGTC TGG 23 (2) INFORMATION FOR SEQUENCE ID NO: 43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43: GAGAACCCAG AGGATCACTG GA 22 (2) INFORMATION FOR SEQUENCE ID NO: 44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44: GGGAAAAGGA CTCAGGGTCT ATC 23 (2) INFORMATION FOR SEQUENCE ID NO: 45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45: GGTGGAAGTG GTCCGCATCG 20 (2) INFORMATION FOR SEQUENCE ID NO: 46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46: GCCCTCCACT GATCTTTAGC AA 22 (2) INFORMATION FOR SEQ ID NO: 47: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47: CGGCCGAAGG AACCTGACCC AG 22 (2) INFORMATION FOR SEQ ID NO: 48: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48: GCTGGAACCC TCACTGGGTT GCC 23 (2) INFORMATION FOR SEQ ID NO: 49: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49: AAGTAGGACC CGAGGCACTG 20 (2) INFORMATION FOR SEQ ID NO: 50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( i) SEQUENCE DESCRIPTION: SEQ ID NO: 50: GAAGAGGAAG AAGCGGTCTG 20 (2) INFORMATION FOR SEQ ID NO: 51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51: TGGAGGACCA GAGGCCCCC 19 (2) INFORMATION FOR SEQ ID NO: 52: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52: GGACGATTAT CAGGAGGCCT GC 22 (2) INFORMATION FOR SEQ ID NO: 53: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53: ACTCAGCTCC TCCCAGATTT 20 (2) INFORMATION FOR SEQ ID NO: 54: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54: GAAGAGGAGG GGCCAAG 17 (2) INFORMATION FOR SEQ ID NO: 55: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55: TCTTGTATCC TGGAGTCC 18 (2) INFORMATION FOR SEQ ID NO: 56: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56: TTGCCAAGAT CTCAGGAA 18

Claims: Claims : 1. Isolated nucleic acid molecule useful as a primer in specifically determining expression of a member of the MAGE family of tumor rejection antigen precursor. 2. The isolated nucleic acid molecule of claim 1, selected from the group consisting of one of SEQ ID NOS: 27-48. 3. A kit useful in determining expression of a MAGE tumor rejection antigen precursor, comprising at least one part of SEQ ID NOS: 27 and 28, 29 and 30, 31 and 32, 33 and 34, 35 and 36, 37 and 38, 39 and 40, 41 and 42, 43 and 44, 45 and 46, and 47-48. 4. Method for determining expression of a MAGE tumor rejection antigen precursor in a cell comprising contacting said cell sample with at least one of the nucleic acid molecules of claim 2 and determining hybridization of said nucleic acid molecule to a target as a determination of expression of MAGE tumor rejection antigen precursor. 5. Method of claim 3, wherein said expression of said tumor rejection antigen precursor is a determination of presence, regression of spread of cancer. 6. The method of claim 5, wherein said cancer is melanoma. 7. The method of claim 5, wherein said cancer is lung adenocarcinoma, said method comprising contacting said sample with a pair of: SEQ ID NOS: 27 and 28, SEQ ID NOS: 47 and 48, or SEQ ID NOS: 49 and 50. 8. The method of claim 4, wherein said cancer is a head squamous cell carcinoma, a neck squamous cell carcinoma, a prostate carcinoma, and a bladder tumor, the method comprising contacting sample with SEQ ID NOS: 27 AND 28, SEQ ID NOS: 29 and 30, SEQ ID NOS: 47 and 48, or SEQ ID NOS: 49 and 50. 9. The method of claim 4, wherein said cancer is a bladder tumor, the method comprising contacting said sample with SEQ ID NOS: 47 and 48, SEQ ID NOS: 49 and 50, or SEQ ID NOS: 51 and 52, followed by amplification. 10. The method of claim 4, wherein said MAGE tumor rejection antigen precursor is MAGE-1, MAGE-2, MAGE-3 or MAGE-4.

Inventors: BOON-FALLEUR THIERRY, BRASSEUR FRANCIS, CHOMEZ PATRICK, DE PLAEN ETIENNE, DE SMET CHARLES, GAUGLER BEATRICE, LETHE BERNARD, MARCHAND M, PATARD JEAN-JACQUES, SZIKORA JEAN-PIERRE, VAN DEN EYNDE BENOIT, VAN DER BRUGGEN PIERRE, WEYNANTS P, BOON-FALLEUR, THIERRY, BRASSEUR, FRANCIS, CHOMEZ, PATRICK, DE PLAEN, ETIENNE, DE SMET, CHARLES, GAUGLER, BEATRICE, LETHE, BERNARD, MARCHAND, M., PATARD, JEAN-JACQUES, SZIKORA, JEAN-PIERRE, VAN DEN EYNDE, BENOIT, VAN DER BRUGGEN, PIERRE, WEYNANTS, P.
Applicants: LUDWIG INST CANCER RES, LUDWIG INSTITUTE FOR CANCER RESEARCH
Application year: 1995
Main classification: C12Q1
IPC codes: C07K14, C12N15, C12Q1